An Act to provide for the control over and regulation of drugs, including habit-forming drugs, and related substances and for matters connected therewith.

Date of Assent: 8th September, 1992.

Date of Commencement: 18th September, 1992.

ENACTED by the Parliament of Botswana

PART I — Preliminary

1. (1) This Act may be cited as the Drugs and Related Substances Act, 1992, and shall apply to all drugs and related substances— including habit-forming drugs.

(2) This Act shall come into operation on such date or dates as the Minister may, by notice in the Gazette, appoint.

2. (1) In this Act, unless the context otherwise requires —  
"advertisement", in relation to a drug, means any written, pictorial, visual or other descriptive matter or verbal statement or reference—  
(a) appearing in any newspaper, magazine, pamphlet or other publication; or  
(b) distributed to members of the public; or  
(c) brought to the attention of the public in any manner whatsoever, which is intended or has the effect of promoting the sale of that drug, and "advertise" shall have a corresponding meaning;  
"drug" means any substance or mixture of substances used or purporting to be suitable for use, or manufactured or sold for use in the diagnosis, treatment, alleviation, modification or prevention of disease, illness, abnormal physical or organic condition or the symptoms thereof, or restoring, correcting or modifying any somatic or psychic or organic condition, and shall include a related substance and, to the extent that it complies with the aforesaid definition, a habit-forming drug;  
"habit-forming drug" means any drug, plant, preparation or substance, or mixture of substances, whether or not otherwise complying with the definition of drug, which is prescribed by the Minister to be a habit-forming drug, and in so prescribing the Minister may prescribe different categories of habit-forming drugs and any special conditions relating thereto;  
"label" when used as a verb means to brand, mark or otherwise designate or describe, and when used as a noun means any brand or mark or any written, printed or graphic matter on the immediate container, or the outside container or wrapper, or attached to or packed with and referring to the contents of the container;
"manufacture" includes all operations involved in the production, processing, compounding, formulation, filling, packaging, re-packaging and labelling of a drug, related substance or a habit-forming drug;
"pharmacist" means a person registered as a pharmacist under the Medical, Dental and Pharmacy Act;
"pharmacy" means premises approved by the Director for the storing, dispensing and selling of drugs and which is under the control of a pharmacist;
"related substance" means any substance or mixture of substances which the Minister, by notice in the Gazette, declares to be a substance to which the provisions of this Act shall apply.

PART II — Control over Drugs

3. (1) No drug shall be imported into or exported from Botswana, or Registration manufactured, distributed or sold unless such drug has been and is registered by the Director of Health Services, hereinafter referred to as "the Director":

Provided that the Minister may, in such special circumstances as he considers constitute justification for such action, by notice in the Gazette —

(a) exempt any drug from the requirements of this section; or
(b) declare any drug to be a banned drug, in which case it shall not be registered or registrable, or if already registered such registration shall be forthwith null and void.

(2) The Director shall keep and maintain, or cause to be kept and maintained, a register in which shall be recorded all drugs registered by him under this section.

(3) The register shall be open for inspection by the public at such times and places and on such terms as may be determined by the Director.

(4) Application for the registration of a drug shall be made to the Director in such form and accompanied by such further information as may be prescribed.

(5) The registration of a drug shall cease to be valid if any significant change has been made in the composition of the product, the dosage form or the conditions of its manufacture without the prior approval of the Director to such change.

4. If, in the opinion of the Director, information not previously Suspension available indicates that a registered drug may not be safe and effective after revocation when used in the manner and for the purposes approved at the time of its registration, he may —

(a) require such revisions in the composition of the drug, its packaging, labelling or advertising as he may consider necessary or desirable to ensure safety and efficacy;
(b) suspend the registration for a specified period or pending compli-
ance with any revisions required under paragraph (a); or
(c) revoke the registration.

5. (1) The Minister may establish a Drugs Advisory Board, the
function of which shall be to advise the Director as to whether a drug
should be registered or not, or as to the conditions subject to which it
should be registered, or whether those conditions should be revised in
accordance with section 4(a), or whether registration should be sus-
pended or revoked.

(2) In establishing the Drugs Advisory Board, the Minister shall
determine its composition and its terms of reference and make all
necessary appointments thereto by notice published in the Gazette.

(3) Members of the Drugs Advisory Board shall hold office for three
years but shall be eligible for re-appointment.

6. (1) The manufacture of drugs may only be, undertaken in an
establishment licensed therefor under the Industrial Development Act,
1988, and with the written approval of the Director.

(2) A person wishing to manufacture drugs shall make application
therefor to the Director in such form as may be prescribed, and shall
supply such further information as the Director may require to satisfy
himself that the premises to be used are satisfactory for the purpose, and
will be operated in accordance with standards of good practice in the
manufacture and quality control of drugs.

(3) The manufacture of drugs shall be under the control of a registered
pharmacist.

(4) Where the Director is satisfied that the conditions of any licence,
or of any approval by him, are not being observed, or that the manufacture
is not being carried out in accordance with the provisions of this Act and
in a satisfactory manner, he may withdraw his approval and give notice
thereof to the manufacturer, whereupon any further such manufacture
shall, unless or until the Director resumes his approval, constitute an
offence under this Act.

7. (1) Drugs shall not be exported or imported, except by the Central
Medical Stores or by a person duly licensed therefor in accordance with
any written law requiring such licence, and with the written approval of
the Director for such export or import.

(2) A person wishing to export or import drugs shall make application
for approval therefor to the Director, in such form as may be prescribed,
and accompanied by such information as the Director may require to
satisfy himself that the applicant has satisfactory premises and that the
business will be operated in accordance with good professional stan-
dards.

(3) The business of exporting or importing drugs shall be under the
control of a technical manager with such qualifications as the Director
may approve.
(4) The distribution of drugs may only be made by establishments or persons approved by the Director for the sale or distribution of such drugs.

(5) Where the Director is satisfied that drugs are being exported, imported or distributed otherwise than in accordance with the conditions of any licence or any other authority required under any other written law, or any approval given by the Director, or the provisions of this Act, or that the business is not being operated in accordance with good professional standards, he may by written notice to the exporter, importer or distributor concerned withdraw his approval for the continued operation of the business, either absolutely or pending compliance with such directions as he considers necessary or desirable.

8. Where drugs are to be imported into Botswana in the course of transit to another country, the importer shall, before such importation, notify the Director in writing, stating —

(a) the type and quantity of the drugs;
(b) the expected time of arrival and departure of the drugs;
(c) the expected method and place of arrival and departure of the drugs; and
(d) the ultimate destination of the drugs, and shall, in writing, notify the Director as soon as possible, and in any event within 48 hours, when such drugs have left Botswana.

9. (1) Drugs shall be classified according to the following classifications and descriptions —

(a) Schedule 1 drug—a drug which is or contains a prescribed habit-forming drug, and must be kept in a pharmacy under the control of a registered pharmacist; such drugs shall be further classified as follows —

Schedule 1A drug — which is highly liable to abuse and which may be dispensed only on written prescription, which prescription must be kept by the dispensing pharmacist for a minimum of three years;

Schedule 1B drug — which is also liable to abuse though not as highly liable as a Schedule 1A Drug, and which may be dispensed only on written prescription;

Schedule 1C drug — which, though widely used therapeutically, is liable to some, but relatively minor, abuse in comparison with a Schedule 1A or a 1B drug, and may be dispensed only on prescription;

Schedule 1D drug— which is unlikely to produce dependence or cause harm if misused, and may be dispensed without prescription;

(b) Schedule 2 drug — a drug, not being or containing a habit-forming drug, which may be dispensed only on written prescription, and which must otherwise be kept in a pharmacy under the control of a registered pharmacist;
A.60
(c) Schedule 3 drug — a drug which may be sold from a pharmacy without prescription, but which must otherwise be kept in a pharmacy;
(d) Schedule 4 drug — a drug which may be sold over the counter by any licensed trader.

(2) Registered medical practitioners and dentists may prescribe all drugs, including Schedule 1 and Schedule 2 drugs, in the exercise of their professions, and the Director may in suitable circumstances authorize limited powers of prescription of any such drugs to pharmacists, registered nurses and other health personnel.

(3) The dispensing of Schedule 1A, B and C drugs, and Schedule 2 and 3 drugs shall be by pharmacists through pharmacies, or through institutions approved by the Director, but regulations made by the Minister may provide for medical practitioners, dentists, pharmacy technicians or other health personnel to dispense such drugs to such extent or in such circumstances as may be specified in such regulations.

(4) Regulations made by the Minister may provide for the keeping of registers with regard to the prescription, dispensing or sale of Schedule 1A and B drugs, and such other drugs as he may consider necessary or desirable.

10. (1) The retailing of drugs, other than Schedule 4 drugs, shall, except as may be otherwise provided in this Act, be through a pharmacy duly licensed as such under the Trade and Liquor Act, and approved for the purpose by the Director, and shall be under the control of a pharmacist.

(2) If the Director is of the opinion that a pharmacy is being operated in an unsatisfactory manner, or not in accordance with good professional standards, he may, in writing to the pharmacy, withdraw his approval, either absolutely or pending compliance with such directions as he considers necessary or desirable.

11. (1) The advertising of any drug shall not, by word or by illustration, give any false, misleading or deceptive information concerning the properties of the drug, or which is likely to encourage wrong or excessive use of the drug.

(2) The advertising of drugs which may be sold on prescription only shall be disseminated solely through professional journals and magazines or only to persons authorized to dispense, prescribe or administer such drugs.

(3) The advertising of drugs which may be dispensed without prescription may be addressed to the public but shall not include promises of unfailing results or expressions or illustrations of a nature likely to offend or intimidate members of the public, or make reference to symptoms in a manner likely to induce members of the public to make wrong diagnoses.
12. (1) All premises where drugs are stored, handled, dispensed, manufactured or sold shall be subject to periodical inspection by persons authorized by the Director in writing for the purpose, and such persons shall be given unhindered access to such premises with the right to take samples, without payment, of any drugs on the premises, and to carry out any investigations that he considers necessary or desirable.

(2) The licence holder of any such premises as are referred to in subsection (1), or the person in charge thereof, shall on demand by the person so authorized by the Director, provide any economic or statistical information required of him, and provide all other necessary assistance required by the authorized person for the performance of his duties.

13. The Director may, by writing under his hand, delegate to the Assistant Director of Technical Support Services or to the Chief Pharmacist, any of his powers under this Act.

14. Any person aggrieved by any decision of the Director, the Appeals Assistant Director of Technical Support Services or the Chief Pharmacist under this Act may appeal to the Minister against such decision.

15. (1) Any person who contravenes or fails to comply with any of the provisions of this Act, Or who —

(a) manufactures, imports, exports, distributes or sells drugs without first obtaining the Director's approval in respect of such drugs;
(b) prescribes any Schedule 1 or Schedule 2 drug without being authorized thereto by this Act or by the Director;
(c) dispenses any Schedule 1 A, B or C drug or any Schedule 2 or 3 drug otherwise than in accordance with the provisions of section 9(3);

(a) advertises any drug otherwise than in accordance with the provisions of section 11; or

(c) obstructs or fails to comply with any reasonable request or demand made by the Director, in the exercise of his powers and the performance of his duties under this Act, shall be guilty of an offence and without prejudice to his liability in accordance with the provisions of subsection (2) or of section 16, shall be liable to a fine of P10 000 and to imprisonment for two years.

(2) Any person who manufactures, imports, exports, distributes, sells, prescribes, dispenses or advertises any drug banned in accordance with a notice by the Minister under section 3(i), or any drug or other substance falsely purporting to be, or intended to or likely to induce anyone to a mistaken belief that it is, a registered drug shall be guilty of an offence and without prejudice to his liability in accordance with the provisions of section 16, shall be liable to a fine of P20 000 and to imprisonment for 5 years.

(3) With regard to any matter in respect of which the Director has delegated his powers to the Assistant Director of Technical Support Services or to the Chief Pharmacist, subsection (1) and section 9(3) shall be read as though for "Director" were substituted the words "Assistant Director of Technical Support Services" or "Chief Pharmacist" respectively.
(4) Where any person is convicted of an offence against this Act or any regulations made thereunder the court may, at the request of the Director, order any drag or other substance in respect of which the offence was committed to be seized and disposed of as the Director may require, and the Director may at the same time withdraw any approval or authorization previously given by him to that person.

PART III — Habit-Forming Drugs

16. (1) Except to the extent and as may be otherwise provided in Part II of this Act, no person —
(a) shall deal in any habit-forming drug or any plant from which any habit-forming drug can be manufactured; or
(b) shall possess or use any such drug or plant.

(2) Any person who contravenes the provisions of subsection (1)(a), shall be guilty of an offence and shall be sentenced to all of the following punishments, namely, to imprisonment, without the option of a fine, and without the suspension of any part thereof, for not less than 10 years or more than 15 years, and to a fine of not less than P15 000 or in default thereof to an additional term of imprisonment of not less than three years or more than five years:

Provided that, in connection with an offence under this subsection relating to cannabis, the punishment shall be imprisonment, without the option of a fine, and without the suspension of any part thereof, for not less than 5 years or more than 10 years, and to a fine of not less than P7 000, or in default thereof to an additional term of imprisonment of not less than one year or more than two years.

(3) Any person who contravenes the provisions of subsection (1)(b), shall be guilty of an offence and, except in connection with an offence relating to the possession of less than 60 grams of cannabis, shall be liable to imprisonment for not less than one year or more than five years, and to a fine of not less than P1 500 or more than P5 000, or in default of payment thereof to imprisonment for not less than one year or more than five years:

Provided that where the offence or offences relate to the possession of—
(a) such habit-forming drags as the Minister may prescribe for the purposes of this proviso; or
(b) 100 or more tablets, capsules or pills, each consisting of or containing any habit-forming drug; or
© any preparation containing 40 grams or more of any habit-forming drug, other than cannabis, the punishment thereof shall be the same as for an offence under subsection (2).

(4) Any person who contravenes the provisions of subsection (1)(b) in relation to the possession of less than 60 grams of cannabis shall be guilty of an offence and liable to a fine of P1 000 and to imprisonment for three years.
(5) Where, upon the trial of a person for an offence in terms of subsection (2), the court considers that the offence has not been proved, but is satisfied that the person is guilty of an offence in terms of subsection (3), the court shall find him guilty of such latter offence and convict and sentence him accordingly.

(6) For the purposes of this section —

"cannabis" includes dagga, Indian hemp, intsang or motokwane, under what ever name it maybe described, sold, supplied or otherwise referred to or dealt with, and whether or not referring to the whole or any portion of the plant, or any extract, tincture, preparation or admixture thereof (other than cannabis indica plasters);

"deal in", in relation to any habit-forming drug or any plant from which such a drug can be manufactured, includes performing any act in connexion with the collection, importation, supply, trans-shipment, administration, exportation, cultivation, manufacture, transmission or prescription thereof;

"possess" includes keep, store or have in custody or under control or supervision.

17. (1) If any police officer has reasonable grounds for believing that any person has committed an offence under this Part or any regulations made under this Act in relation to this Part he may —

(a) enter without a search warrant upon any land, and there require any such person to produce for his inspection any habit-forming drug in his possession, or any permit or licence or other authorization issued to him or required to be kept by him under the provisions of this Act or any regulations made there under;

(b) without a search warrant search such person or any animal in the possession of such person, and enter and search any land, building, vehicle, aircraft or boat in the possession or use of such person, and open and search any receptacle or thing in the possession of or under the control of such person:

Provided that whenever a woman is searched the search shall be conducted by a woman with strict regard for decency, and if there is no female member of the Botswana Police Force available, the search may be conducted by any woman specially named for the purpose by a peace officer;

(c) seize any habit-forming drug or any article or substance which he suspects to be a habit forming drug, or any plant from which any such drug can be derived, extracted, produced or manufactured, or any pipe, receptacle or material for smoking opium, or cannabis, in the possession of such person, and any vehicle, aircraft, boat, receptacle, animal or thing in or upon which such habit-forming drug, article, substance, plant, pipe, receptacle or material was found, and unless he is satisfied that such person will appear and answer any charge which may be preferred against him, arrest him without warrant and detain him;
(d) undertake any inspection which he may deem necessary to determine whether the provisions of this Act and any regulations made thereunder in respect of habit-forming drugs are being complied with.

2. Every person who is detained and everything seized under the provisions of subsection (1) shall be taken as soon as is reasonably possible before a court to be dealt with according to law.

18. (1) Notwithstanding anything to the contrary in any written law, any Magistrate Grade I, Senior Magistrate or Principal Magistrate shall have special jurisdiction to impose any penalties provided in this Act for any contravention of the provisions of this Part, or any regulations made under this Act relating to this Part, or to exercise any of the powers provided therein in respect of such contraventions.

(2) Where any person is found guilty of any contravention of the provisions of this Part or any regulations made under this Act relating to this Part, the court shall order any habit-forming drug, plant, pipe, receptacle or material in respect of which the offence was committed to be forfeited to the State.

(3) Where any person is found guilty of any contravention of the provisions of this Part or any regulations made under this Act relating to this Part, the court shall order that any vehicle, aircraft, boat, animal, receptacle or thing in or upon which such habit-forming drug, plant, pipe, receptacle or material was found to be detained for a period of 28 days, and, if within such period no successful application is made under subsection (4), it shall be thereafter forfeited to the State.

(4) If, upon application being made to it within 28 days of the date of the order made under subsection (3) by a person claiming ownership, the court is satisfied that —

(a) such vehicle, aircraft, boat, animal, receptacle or thing is not the property of the person convicted; and

(b) the claimant is the owner; and

(c) that he did not know that it was being used for an illegal purpose, or was not able to prevent its use by the person convicted, it may, if it considers it to be equitable and expedient to do so, order the return thereof to the claimant.

(5) If the convicted person used any motor vehicle to carry or convey the drug, plant, pipe, receptacle or material in respect of which the offence was committed, the court may suspend any driver's licence issued to that person, and disqualify him from driving for a period not exceeding five years, and may cancel any licence issued in respect of that vehicle in terms of the Road Traffic Act, and may order that such vehicle should not be relicensed for a period not exceeding five years.
(6) If the convicted person is the holder of any licence issued under the provisions of any written law relating to the issue of trading licences, and it is proved to the satisfaction of the court that he used the licence to conceal or assist him in concealing the offence, the court may cancel the licence, and may declare that person to be disqualified from obtaining another such licence for a period not exceeding five years.

(7) For the avoidance of doubt, it is hereby declared that the provisions of subsections (2), (3), (5) and (6) shall be in addition to and not in derogation of any other penalties imposed under this Act.

(8) Anything forfeited to the State under the provisions of this section shall be disposed of as the Minister may direct.

19. (1) Any duly registered medical practitioner, dentist or pharmacist vicarious shall be deemed guilty of and shall be liable to the penalties prescribed liability for contraventions of this Part in respect of habit-forming drugs where the act or default constituting an offence was that of a partner, manager, clerk, drags agent, apprentice or servant associated with or employed by him, unless he satisfies the court/that such act or default was committed without his knowledge and was not due to his negligence in the supervision or direction of such partner, manager, clerk, agent, apprentice or servant.

(2) Every director and manager of a company, who is resident in Botswana, shall be liable for and subject to the penalties prescribed for any contravention of the provisions of this Part in relation to habit-forming drugs by such company.

20. (1) If in any charge under this Part it is alleged that cannabis, as defined in section 16, was being cultivated, evidence that such cannabis was found in cultivated land shall be sufficient proof that it was being cultivated with the knowledge of the owner or occupier of such land, unless the contrary is proved.

(2) Any person who is upon or in charge of or who accompanies any vehicle, aircraft or animal in or upon which there is any habit-forming drug, or any plant or portion of a plant from which any such drug can be extracted, derived, produced or manufactured shall, until or unless the contrary is proved, be deemed for the purposes of this Part, to be the possessor of such drug, plant or portion of a plant.

(3) The burden of proving any fact which would be a defence to a charge of contravening any provision of this Part shall lie upon the person charged.

(4) Every person required by this Part to be in possession of a permit, licence, prescription, approval or any other authority shall be deemed to be without such permit, licence, prescription, approval or authority unless he produces or gives satisfactory proof of possessing the same.

(5) In any indictment, summons or other form of charge under this Part, it shall be sufficient to set forth the offence charged in the words of this Part or in similar words, without negating any exception, exemption or qualification.
PART IV — Miscellaneous

21.(1) The Minister may make regulations for the better carrying out of the provisions and purposes of this Act, and without prejudice to the generality of the foregoing, such regulations may provide for —
(a) any matter to be prescribed under this Act;
(b) the procedure for the registration of drugs, and the cancellation or suspension of such registration;
© the procedure for obtaining the approval of the Director in any matter where the approval of the Director is required under this Act, and for the withdrawal or suspension of such approval;
(d) the control and regulation of the manufacture, import, export, distribution and sale of drugs;
(e) the labelling and advertising of drugs;
(f) forms to be used and fees to be paid in respect of applications under this Act;
(g) the inspection of premises under this Act;
(h) the control, conduct and regulation of clinical trials of any drug, or any scientific or medical experiments in relation to habit-forming drugs.

(2) Regulations under this Act may provide penalties for breaches thereof of fines up to a maximum of P2 000 and imprisonment for not more than one year.

22. The Drags Act, 1991 and the Habit-Forming Drugs Act are hereby repealed.

PASSED by the National Assembly this 3rd day of August, 1992.

CG. M0K0B1,
Clerk of the National Assembly.
REGULATION
1. Citation
2. Drugs Advisory Board
3. Registration of drugs
4. Exemption from registration
5. Approval for the manufacture, etc. of drugs
6. Records to be kept by manufacturer of drugs
7. Import, export and distribution of drugs
8. Labelling of drugs
9. Recall of drugs
10. Prescription of drugs
11. Dispensing of Schedule 1A and IB drugs
12. Dispensing of Schedule 1C drugs
13. Dispensing of Schedule 2 drugs
14. Dispensing of drugs by nurses
15. Dispensing, general
16. Emergency supply of drugs
17. Registers and records
18. Clinical trials
19. Appeals
20. Classification of drugs
21. Prescribed habit forming drugs
22. Forms
   First Schedule
   Second Schedule
   Third Schedule

IN EXERCISE of the powers conferred by section 21 of the Drugs and Related Substances Act, 1992, the Minister of Health hereby makes the following Regulations —
1. These Regulations may be cited as the Drugs and Related Substances Regulations, 1993.
2. (1) In accordance with the provisions of section 5 of the Drugs and Related Substances Act, 1992, there is hereby established a Drugs Advisory Board, hereinafter referred to as "the Board", for the purposes specified in that section.
   (2) The Board shall consist, of the following persons or their alternates appointed by the Minister —
(a) a hospital pharmacist;
(b) a physician in the service of the Government;
© a district medical officer;
(d) a quality control pharmacist in the service of the Government;
(e) a duly registered medical practitioner from the private sector;
(f) a registered pharmacist from the private retail sector;
(g) a pharmacist from the Drugs Regulatory Unit; and
(h) such other members as the Minister may determine.
(3) Members of the Board shall hold office for a period of three years, but shall be eligible for re-appointment, and the Minister may at any time revoke the appointment of any member, or may grant leave of absence to any member, if he thinks it desirable or expedient to do so.
(4) The appointment, resignation or the revocation of the appointment of any member of the Board shall be notified by the Minister by notice in the Gazette.
(5) The Minister shall appoint a public officer to be the Secretary of the Board.
(6) The Board shall elect from amongst its members a Chairman to preside over meetings of the Board, and a Deputy Chairman to act as Chairman whenever the substantive holder of the post is unable to attend.
(7) The Board shall meet at such times, and as often as may be necessary or expedient for the proper carrying out of its duties under the provisions of the Act:

Provided that intervals between meetings of the Board shall never be greater than three months.
(8) The Board may co-opt one or more persons qualified or able to assist it or advise it in its functions under the Act, to attend any meeting or meetings of the Board, but such person or persons may not vote on any matter before the Board.
(9) The members of the Board and any expert assisting the Board shall observe and preserve the confidentiality of all matters coming before the Board, and such professional discretion shall subsist even after the termination of their terms of office or of their expert mandates.
(10) The Secretary shall keep minutes of each meeting of the Board, which shall be submitted for acceptance at the next meeting of the Board.
Except as is otherwise provided in this regulation, the Board shall be responsible for regulating its own proceedings.
3. (1) An application to register a drug, or for the renewal of such registration shall be made to the Director in Form 1 in the Schedule hereto and shall be accompanied by a fee of P800 for a drug which is imported, P400 for a drug which is partially locally manufactured and P200 for a drug which is totally locally manufactured.
(2) The Director shall submit any such application to the Board, together with his own recommendations and any relevant comments, for consideration by the Board, and he shall abide by any advice tendered by the Board.
(3) Where a drug is approved for registration, or for renewal of registration, the Director shall issue to the applicant a certificate of registration in Form 2 in the Schedule, and if the drug is not approved for registration or renewal of registration, he shall so inform the applicant, giving the reasons for such disapproval, at the same time informing the applicant of his right to appeal against such disapproval.
(4) Where a drug is approved for registration, or re-registration, subject to conditions, the applicant shall be informed of such conditions and shall comply therewith.

(5) A certificate of registration shall be valid for five years or such lesser period as the Director may, in any particular case specify, and provided that an application for the renewal of registration is made at least six months before the date of expiry, such validity shall extend until a decision is made and communicated to the applicant.

(6) When a drug is registered, the following information shall be recorded in the drug register kept by the Director in accordance with section 3(2) of the Act —

(a) the name of the drug approved;
(b) the registration number allocated to the drug;
(c) the approved chemical name or international non-proprietary name (INN) of each active ingredient of the drug, and the quantity thereof contained in a dosage unit or per suitable mass or volume or unit of the drug;
(d) the dosage form of the drug;
(e) the conditions of registration of the drug;
(f) the name of the applicant; and
(g) the date of registration of the drug.

4. (1) The following drugs shall be exempted from registration —

(a) any drug manufactured or imported by the Central Medical Stores for specific therapeutic use;
(b) any drug imported through the Central Medical Stores as a donation to the Government or to a Government hospital or to a hospital run by a Mission for use in that hospital;
(c) any drug imported under the authority of the Director, or any person authorized by him, for experimental use in hospitals or for specific therapeutic use or scientific research or tests;
(d) any drug prepared extemporaneously by a pharmacist for use as prescribed by a medical practitioner;
(e) any non-scheduled herb used for traditional medicine and exempted by the Director;
(f) any preparation not containing active ingredients in excess of one milli/gram part of the preparation's own weight.

(2) The prior approval by the Director shall be sought in the circumstances specified in paragraphs (a) and (b) of subregulation (1), but where this is not practical such approval shall be sought as soon as is, in the circumstances, reasonably possible thereafter.

(3) The Director shall make records of exempted drugs imported or manufactured under the provisions of paragraphs (a), (b) and (c) of sub-regulation (1), the quantity imported and the name and address of the person or organization who imported or manufactured any such drug.

5. (1) Any person wishing to manufacture, import, export, distribute or sell drugs shall apply to the Director for approval in Form 3 in the Schedule, accompanied by a fee of P50, and the approval of the Director, if given, shall be in Form 4 in the Schedule.

(2) If an application is not approved, the Director shall so inform the applicant, giving the reasons for such refusal.
(3) Any approval shall be valid for a period of five years, or such lesser period as may, in any particular case, be specified by the Director, and provided that an application for the renewal of approval is made at least two months before the date of expiry of such approval, the validity thereof shall extend until a decision is made and communicated to the applicant.

6. (1) A manufacturer of drugs shall keep and maintain and hold readily available for inspection, comprehensive records containing details of—
   (a) all steps taken in the storage and testing of raw materials;
   (b) all steps taken in the manufacture of each batch of drugs;
   (c) all tests carried out on representative samples; and
   (d) the sale and distribution of each batch of drugs.

(2) The records required to be kept in accordance with sub-regulation (1) shall be retained for at least 5 years from the date of manufacture, or for one year from the date of expiry of the relevant batch of drugs, whichever is the longer.

(3) The manufacturer shall, without any undue delay, report in writing to the Director any intention.—
   (a) to change the process of manufacture, or the method of testing any drug; or
   (b) to alter materially the establishment, where such alteration will or is likely to affect the conditions under which approval for the manufacture of drugs was given.

7. (1) Importers, exporters and distributors of drugs (and for the purpose of this regulation "distributor" includes wholesaler and retailer, and "distribution" shall be construed accordingly) shall keep and maintain records containing all details of the importation, wholesale and distribution of drugs by them, and such records shall be retained and kept available for inspection by a police officer, or by any person so authorized therefor by the Director for a period of at least five years from the date of each relevant entry.

(2) Any person wishing to import or export a Schedule 1A, IB or IC drug shall—
   (a) in the case of import, apply for the approval of the Director therefor on Form HFD 1 in the Schedule, and any such approval shall be in given on Form HFD 2 in the Schedule specifying such quantities of the drug as may be so imported, and any such approval shall be valid for three months, or such lesser period as may be specified therein; or
   (b) in the case of export, apply for the approval of the Director on Form HFD 3 in the Schedule, and any such approval shall be given on Form HFD 4 in the Schedule specifying such quantities of the drug as may be exported out of Botswana, and any such approval shall be valid for three months, or such lesser period as may be specified therein.

(3) The export, import and distribution of all drugs other than Schedule 4 drugs shall be—
   (a) in a private pharmacy, a referral or district hospital pharmacy, a private hospital pharmacy or in any other place authorized by the Director to sell such drugs, under the control of a pharmacist;
   (b) in a private medical practice or surgery or in a Government primary hospital, under the control of a pharmacy technician under the supervision of the medical practitioner concerned or of a medical officer, as the case may be;
   (c) in a private dental surgery or practice, under the control of the dentist in charge; or
(d) in a clinic or health post, under the control of a registered or enrolled nurse approved by the Director.

8. (1) The container of every drug imported, manufactured, processed or packed in Botswana shall bear a label written in English, with the following information clearly indicated thereon —

(a) either the approved name of the drug as used in official pharmacopoeias or formularies, or the international non-proprietary name;
(b) the brand name, if any;
(c) the contents of the container;
(d) the quantity of active ingredients per dosage unit;
(e) the name of the manufacturer;
(f) the batch identification;
(g) the expiry date;
(h) any special storage conditions that may be necessary or desirable;
(i) any warnings or precautions that may be necessary or desirable.
(j) any directions for use if sold without prescription; and
(k) any appropriate statutory or restrictive direction or label in the Schedule that may be necessary.

(2) In any special circumstances the Director may, where he considers it desirable, exempt any particular consignment of drugs from the requirements of sub-regulation (1).

(3) The container of every drug dispensed to a patient shall have a label bearing the following information —

(a) the full name of the patient;
(b) the date of dispensing;
(c) the name of the pharmacy or other health facility dispensing it;
(d) all information required for the purposes of sub-regulation (1) with the exception of paragraphs (b), (e) and (f) thereof.

(4) The container of any drug exempted from registration shall as far as possible bear the information required under sub-regulation (1).

(5) In respect of those drugs listed in regulation 21, against which a label and a number in parenthesis is indicated, any such drug shall bear a label giving information or instructions in accordance with the following —

<table>
<thead>
<tr>
<th>Label number</th>
<th>Word Content</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1)</td>
<td>&quot;Contains aspirin&quot; (unless name of product includes word &quot;aspirin&quot;); plus &quot;If symptoms persist, consult your doctor&quot;; plus the recommended dosage; plus &quot;Do not use on children under 12 years except on medical advice.&quot;</td>
</tr>
<tr>
<td>(2)</td>
<td>&quot;Contains an aspirin derivate&quot;; plus &quot;If symptoms persist, consult your doctor&quot;; plus the recommended dosage.</td>
</tr>
<tr>
<td>(3)</td>
<td>&quot;Contains paracetamol&quot; (unless the name of the product includes the word &quot;paracetamol&quot;); plus &quot;If the symptoms persist, consult your doctor&quot;; plus &quot;Do not exceed the stated dose&quot;; plus the recommended dosage.</td>
</tr>
<tr>
<td>(4)</td>
<td>&quot;Warning. Asthmatics should consult their doctor before using this product.&quot;</td>
</tr>
</tbody>
</table>
9. Whenever the Director finds that any portion of any batch of drugs does not conform to the standards of identity, strength, quality and purity, or any other requirement specified in the documentation for registration, he may instruct the licensee to discontinue the sale of the remainder of the batch and, so far as is practicable, to recall any portion of the batch already sold.

10. (1) Prescriptions of drugs shall be written in generic or approved international non-proprietary names (INN) except when a particular brand of drug is preferred and clinically acceptable reasons for such preference are communicated to the dispenser.

(2) Where a prescription is written using a generic or approved international non-proprietary name the least expensive drug of that description in the pharmacy shall be sold or dispensed for that prescription.

(3) In granting limited powers of prescription of Schedule 1, 2 and 3 drugs under section 9(2) of the Act, the Director may grant to —

(a) registered nurses in hospitals or Government clinics specializing in medical fields such as ophthalmology, psychiatry, midwifery, or as a registered family nurse practitioner, power to prescribe only those drugs specific to their speciality or training and, where applicable, which are specified for them in the Botswana National Drug Formulary;

(b) registered nurses and enrolled nurses in Government clinics and health posts, power to prescribe only those drugs which are specified for them in the Botswana National Drug Formulary;

(c) dental therapists, power to prescribe only those drugs specified for them in the Botswana National Drug Formulary; and

(d) registered pharmacists power to prescribe drugs only in the circumstances referred to in regulation 12.

11. (1) Schedule 1A and 1B drugs may only be dispensed or sold by a pharmacist upon a written prescription, by a medical practitioner or dentist, presented for dispensing within thirty days of the date of its issue, and for the supply of a quantity not greater than is indicated on the prescription, which shall not in any case exceed thirty days supply, and any such prescription shall be retained in the pharmacy for a period of three years after the date of dispensing.
(2) The dispenser or seller of a Schedule 1A or IB drug shall enter a record of such sale or dispensing, as the case may be, in an appropriate register, which register shall be kept for a period of five years after the last relevant entry therein.

(3) Separate registers shall be kept for Schedule 1A drugs and for Schedule IB drugs.

(4) Except when being administered to a patient, every Schedule 1A and Schedule IB drug shall be kept under safe custody in a lockable cabinet or in a safe.

(5) The destruction of any Schedule 1A or Schedule IB drug, in part or whole, shall be reported in writing to the Director, and, except where the destruction is accidental, shall be supervised by a pharmacist and witnessed by a police officer.

12. Schedule 1C drugs may only be dispensed or sold by a pharmacist upon a written prescription of a medical practitioner or dentist presented for dispensing within thirty days from the date of issue thereof, and for the supply of a quantity of the drug not in excess of that indicated on the prescription, and in any case not exceeding thirty days supply, and any such prescription shall be retained in the pharmacy for a period of not less than three years from the date of the last sale or dispensing:

Provided that where the prescribing medical practitioner or dentist is personally known to the dispensing pharmacist and is confirmed as being a medical practitioner or dentist, and the pharmacist is satisfied that it is impossible or impracticable to obtain a written prescription within a time that is reasonable in all the circumstances, he may dispense a prescription made by telephone or facsimile, in quantities not exceeding those stated above, on condition that a written prescription will be provided within 48 hours.

13. Schedule 2 drugs may be dispensed —

(a) in referral hospitals, district hospitals, mission hospitals, mine hospitals or private hospitals by a pharmacist or an intern pharmacist, or by a pharmacy technician under the supervision of a pharmacist, and upon a written prescription issued by a medical practitioner or a dentist;

(b) in a retail pharmacy by a pharmacist, or by a pharmacy technician under the supervision of a pharmacist, and upon a written prescription issued by a medical practitioner or a dentist; or

(c) in a private medical practice or surgery or a Government primary hospital, by a pharmacy technician upon a written prescription issued by a medical practitioner or a medical officer.

14. Notwithstanding regulations 11, 12 and 13, registered and enrolled nurses in referral, district, primary, mine, mission and private hospitals, clinics, health posts and mobile clinics, may, in the exercise of their duties, dispense Schedule 1A, IB, 1C, 2 and 3 drugs to patients, upon written prescription by a medical practitioner or a dentist.

15. (1) The dispenser of any drug shall not dispense a quantity thereof greater than the amount stated in the prescription.

(2) A prescription may be repeated without further prescription if it so endorsed by the prescriber.

(3) Except as is otherwise provided in these Regulations or where a shorter period is endorsed thereon, a prescription shall be valid for dispensing for a period not exceeding twelve months from the date of issue.
(4) The dispenser of a drug shall endorse on the prescription the date when it is dispensed, the quantity dispensed, and shall append his signature thereto.

16. (1) In an emergency a Schedule 2 drug can be supplied or dispensed as provided in regulation 13, but without a prescription if—
   (a) there is an immediate need for the drug requested to be supplied and it is impracticable in the circumstances to obtain a prescription; or
   (b) the treatment with the drug has on a previous occasion been prescribed for the person requesting it.

(2) The quantity of the drug to be supplied in accordance with subregulation (1) shall not exceed five days' treatment:

Provided that —
   (a) where the drug in question is an ointment, a cream or an aerosol for the relief of asthma, which has been made up for sale in a container elsewhere than at the place of supply, the dispenser may supply the smallest pack available;
   (b) where the drug in question is an oral contraceptive, the dispenser may supply a sufficient quantity for a full cycle; or
   (c) where the drug required is in such a package that its impractical to split the package, the whole package may be supplied.

17. (1) Separate registers shall be kept for Schedule 1A and Schedule 1B drugs.

   (2) Registers to be kept by the manufacturer, seller, importer, exporter or distributor of such drugs shall contain the following information, as appropriate —
      (a) the approved name and quantity of the drug concerned;
      (b) the name and business address of the supplier;
      (c) the date on which the drug was received;
      (d) the import permit number in the case of imports;
      (e) the export permit number in the case of exports;
      (f) the name and business address of the purchaser;
      (g) the date of sale of the drug;
      (h) the invoice or reference number of such sale.

   (3) Registers to be kept by the dispenser of such drugs in accordance with regulation 11(2) shall contain the following information, as appropriate —
      (a) the approved name and quantity of the drug concerned;
      (b) the name and business address of the supplier;
      (c) the date on which the drug was received;
      (d) the import permit number in the case of imports;
      (e) the name and address of the person to whom the drug was dispensed;
      (f) the prescription number or reference number upon which the drug was dispensed;
      (g) the date of such dispensing;
      (A) the name and address of the prescriber.

(4) All invoices for the purchase or supply of Schedule 1A, IB and 1C drugs shall be kept for a minimum of five years.

(5) All registers or records required to be kept under this regulation must be retained for a period of five years after the date of the last relevant entry, and shall be kept available for inspection by authorized officers.

(6) All registers and records required to be kept under these Regulations shall be balanced at the end of every calendar month.
18. (1) Clinical trials of drugs means studies in humans or animals in order to systematically generate new or verify existing information about their efficacy and their side effects, and also studies relating to their absorption in, metabolism and excretion from the human or animal body.

(2) Any person wishing to conduct a clinical trial of a drug shall submit to the Director an application signed by the applicant, and if the Director approves he shall issue a written authorization permitting the applicant to conduct such trial, with or without such conditions or directions as he may specify.

(3) To ensure protection of the general public against any risk or adverse effects from the clinical trial of any drug the Director shall monitor the trial from the beginning to the end so as to satisfy himself that all specific and general conditions or directions subject to which the trial was authorized are being strictly observed by the person conducting the trial, and that to all intents and purposes the trial will achieve its aims and objectives.

(4) If at any stage during the clinical trial of any drug the Director is satisfied that, having due regard to the initial risks, discomforts or other adverse effects caused to persons taking part in the trial, it is in the public interest immediately to stop or suspend the trial, he may, in writing, so notify the person conducting the trial, who shall immediately comply with such notice.

(5) Where a clinical trial is to be conducted in a hospital or other medical institution, the application therefor shall be countersigned by the medical superintendent, or by a senior medical officer of comparable rank of such hospital or medical institution.

(6) Any person who is aggrieved, by a decision of the Director not to grant approval for the conduct of a clinical trial may appeal against such decision to the Minister.

19. Any appeal lodged in accordance with the provisions of section 14 of the Act or regulation 18(6) shall be lodged within thirty days after the date when the decision appealed against is communicated to the applicant.

20. For the purposes of the Act and these Regulations drugs shall be classified in accordance with the lists set out in the First Schedule.

21. For the purposes of the definition of "habit forming drug", section 3(l)(b) and Part III of the Act the drugs listed in the Second Schedule are declared to be banned habit forming drugs.

22. The forms to be used for the purposes of the Act shall be in accordance with the forms set out in the Third Schedule.
FIRST SCHEDULE  (reg. 20)

<table>
<thead>
<tr>
<th>(1) SCHEDULE 1 DRUGS</th>
<th>Category</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetorphine; its salts; its esters and ethers; their salts</td>
<td>1A</td>
</tr>
<tr>
<td>Acetorphine hydrochloride</td>
<td>1A</td>
</tr>
<tr>
<td>Acetyldihydrocodeine; its salts but if for non-paxenteral use and:</td>
<td></td>
</tr>
<tr>
<td>(a) in undivided preparations with ms 2.5% (calculated as base: Schedule 2)</td>
<td>ID</td>
</tr>
<tr>
<td>(b) in single-dose preparations with ms per dosage unit lOOmg (calculated as base: Schedule 2)</td>
<td>ID</td>
</tr>
<tr>
<td>Acetyl-methadol see Methadyl acetate</td>
<td></td>
</tr>
<tr>
<td>Alfentanil</td>
<td>1A</td>
</tr>
<tr>
<td>Allobarbital</td>
<td>1C</td>
</tr>
<tr>
<td>Allyprodine; its salts</td>
<td>1A</td>
</tr>
<tr>
<td>Alphacetylmethadol; its salts; its esters and ethers; their salts</td>
<td>1A</td>
</tr>
<tr>
<td>Alphameprodine; its salts</td>
<td>1A</td>
</tr>
<tr>
<td>Alphaprodine; and its salts</td>
<td>1A</td>
</tr>
<tr>
<td>Amfetramione</td>
<td>IB</td>
</tr>
<tr>
<td>Amidone see Methadone</td>
<td></td>
</tr>
<tr>
<td>Alphapethadone; its salts, its esters and ethers; their salts</td>
<td>1A</td>
</tr>
<tr>
<td>Amphetamine; its salts</td>
<td>1A</td>
</tr>
<tr>
<td>Amphetamine phosphate</td>
<td>1A</td>
</tr>
<tr>
<td>Amphetamine sulphate</td>
<td>1A</td>
</tr>
<tr>
<td>Amylobarbital</td>
<td>IB</td>
</tr>
<tr>
<td>Amylbarbitone sodium</td>
<td>IB</td>
</tr>
<tr>
<td>Anileridine; its salts</td>
<td>1A</td>
</tr>
<tr>
<td>Barbitone</td>
<td>1C</td>
</tr>
<tr>
<td>Barbitone sodium</td>
<td>1C</td>
</tr>
<tr>
<td>Benzethidine; its salts</td>
<td>1A</td>
</tr>
<tr>
<td>Benzphetamine; its salts</td>
<td>IB</td>
</tr>
<tr>
<td>Bezphetamine hydrochloride</td>
<td>IB</td>
</tr>
<tr>
<td>Benzylmorphine; its salts; its esters and ethers; their salts</td>
<td>1A</td>
</tr>
<tr>
<td>Benzylmorphine hydrochloride</td>
<td>1A</td>
</tr>
<tr>
<td>Betacetylmethadol; its salts</td>
<td>1A</td>
</tr>
<tr>
<td>Betameprodine; its salts</td>
<td>1A</td>
</tr>
<tr>
<td>Betamethadone; its salts; its esters and ethers; their salts</td>
<td>1A</td>
</tr>
<tr>
<td>Betamoisopropylbenzene see amphetamine</td>
<td></td>
</tr>
<tr>
<td>Betaprodine; its salts</td>
<td>1A</td>
</tr>
<tr>
<td>Bezitramide; its salts</td>
<td>1A</td>
</tr>
<tr>
<td>Bromazepam</td>
<td>1C</td>
</tr>
<tr>
<td>Buprenorphine</td>
<td>IB</td>
</tr>
<tr>
<td>Buprenorphine hydrochloride</td>
<td>IB</td>
</tr>
<tr>
<td>Butalbital</td>
<td>IB</td>
</tr>
<tr>
<td>Butobarbitone</td>
<td>1C</td>
</tr>
<tr>
<td>Butobarbitone sodium</td>
<td>1C</td>
</tr>
<tr>
<td>Camazepam</td>
<td>1C</td>
</tr>
<tr>
<td>Carfentanil; its stereoisomers, its salts; its esters and ethers, their salts</td>
<td>1A</td>
</tr>
<tr>
<td>Cathine; its salts; its stereoisomers not being phenylpropanolamine; their salts</td>
<td>IB</td>
</tr>
<tr>
<td>Chlordiazepoxide</td>
<td>1C</td>
</tr>
<tr>
<td>Chlordiazepoxide hydrochloride</td>
<td>1C</td>
</tr>
</tbody>
</table>
Chiorphentermine; its salts                              IB
Chlorphentermine hydrochloride                          IB
Clodazapam                                             IC
Clonazepam                                             IC
Clonitazene; its salts                                   IA
Clorazepate                                            IC
Clotiazepam                                            IC
Cloxazolam                                             IC
Codeine; its salts but if for non-parenteral use and:   IA
    (a) in undivided preparations with ms 2.5% (calculated as base: Schedule 2) ID
    (b) in undivided preparations with ms 1.5% (calculated as base: and not more than 200ml: Schedule 3) ID
    (c) in single-dose preparations with ms per dosage unit 100mg (calculated as base: Schedule 2) ID
    (d) in single-dose preparations with ms per dosage unit 1.5% (calculated as base, and md 100mg: or calculated as base, and not more than 30 tablets: Schedule 3) ID
Codeine hydrochloride see Codeine
Codeine phosphate see Codeine
Codeine sulphate see Codeine
Codoxime see Dihydrocodeinone O-carboxymethyloxime
4-cyano-2-dimethylamino-4,4-diphenylbutane; its salts  IA
4-cyano-1-methyl-4-phenylpiperidine; its salts         IA
Cyclobarbitone                                         IB
Delorazepam                                            IC
Delta-9-tetrahydrocannabinol see Dronabinol
Desomorphine; its salts; its esters and ethers; their salts IA
Desoxyphedrine see Methylamphetamine
Desoxynorephedrine see Amphetamine
Dexamphetamine; its salts                               IA
Dexamphetamine phosphate                                IA
Dexamphetamine sulphate                                 IA
Dextrodiplphenopyradine see Dextromoramide
Dextromoramide; its salts                                IA
Dextromoramide tartrate                                  IA
Dextropropoxypnene; its salt; its esters and ethers; their salts IA
but in a preparation for oral use containing not more than 135mg of dextropropoxypnene (calculated as base, per dosage unit, or with a total concentration of not more than 2.5% calculated as base, in undivided preparations: Schedule 2) ID
Diampropicn; its salts                                   IA
Diazepam                                               IC
Diethylproplin hydrochloride                             IB
Diethylthiambutene; its salts                           IA,
Diethylthiambutene hydrochloride                        IA
Difenoxin (1-(3-cyano-3,3-diphenyl-propyl)-4-phenylpiperidine-4-carboxylic acid) IA
(but if in preparation containing, per dosage unit, not more than 0.5mg of difenoxin and a quantity of atropine sulphate equivalent to at least 5% of the dose of difenoxin: Schedule 2) ID
Dihydrocodeine; its salts
   but if for non-parenteral use and:
   (a) in undivided preparations with ms 2.5% (calculated as base: Schedule 2) ID
   (b) in undivided preparations with ms 1.5% (calculated as base) and md IOMg (calculated as base: Schedule 3) ID
   (c) in single-dose preparations with ms per dosage unit IOOmg (calculated as base: Schedule 2) ID
   (d) in single-dose preparations with ms per dosage unit 1.5% (calculated as base) and md IOMg (calculated as base: Schedule 3) ID
Dihydrocodeine phosphate; see dihydrocodeine
Dihydrocodeine tartrate; see dihydrocodeine
Dihydrocodeinone see hydrocodone
Dihydrocodeinone enol acetate see Thebacon
Dihydrocodeinone O-carboxymethyl-oxime; its salts; its esters and ethers; their salts 1A
   Dihydrocodeinone see Desomorphine
   Dihydrohydrocodeinone; see Oxycodeone
   Dihydrohydroxymorphinone; see Oxymorphone
   Dihydromorphine; its salts; its esters and ethers; their salts 1A
   Dihydromorphinone see hydromorphone
   Dimenoxadole; its salts 1A
   Dimepheptanol; its salts; its esters and ethers; their salts 1A
   Dimethylthiambutene; its salts 1A
   Dioxaphetyl butyrate; its salts 1A
Diphenoxylate; its salts 1A
   but if in preparation with ms per dosage unit 2.5mg of diphenoxylate (calculated as base, and quantity of atropine sulphate equivalent to at least 1% of the dose of diphenoxylate: Schedule 2) ID
Diphenoxylate hydrochloride; see diphenoxylate
Dipipanone; its salts 1A
   Dipipanone hydrochloride 1A
   Dronabinol 1A
   Drotebanol; its salts; its esters and ethers; their salts 1A
   Etozolam 1C
   Ethchlorvynol 1C
   Ethinimate 1C
   Ethyl loflazepate 1C
   N-Ethylamphetamine; its salts; its stereoisomers; their salts 1C
   Ethylmethylthiambutene; its salts 1A
   Ethylmorphine; its salts 1A
   but if for non-parenteral use and:
   (a) in undivided preparations with ms 2.5% (calculated as base: Schedule 2) ID
   (b) in single dose preparations with ms per dosage unit IOOmg (calculated as base: Schedule 2) ID
Ethylmorphine hydrochloride see Ethyl morphine
Etonitazene; its salts 1A
Etorphine; its salts; its esters and ethers; their salts 1A
Etorpmone hydrochloride 1A
Etoxeridine; its salts; its esters and ethers; their salts 1A
Fencamfamin; its salts; its stereoisomers; their salts IC
Fenethylline; its salts; its stereoisomers; their salts 1A
Fenproporex; its salts; its stereoisomers; their salts IB
Fentanyl; its salts 1A
Fludiazepam IC
Flunitrazepam IC
Flurazepam hydrochloride; its salts IC
Flurazepam monohydrochloride IC
Furethidine; its salts IA
Glutethimide; its salts; its stereoisomers; their salts IA
Halazepam IC
Haloxazolam IC
Heptobarbitone IC
Hexobarbitone IC
Hexobarbitone sodium IC
Hydrocodone; its salts IA
Hydrocodone bitartrate IA
Hydromorphinol; its salts; its esters and ethers; their salts IA
Hydromorphone; its salts; its esters and ethers; their salts IA
Hydroxyperididine; its salts; its esters and ethers; their salts IA
Isomethadone IA
Ketazolam IC
Ketobemidone; its salts; its esters and ethers; their salts IA
Lefetamine(SPA) - IB
Levamfetamine IA
Levomethamphetamine IA
Levomethorphan; its salts IA
Levomoramide; its salts IA
Levophenacylmorphine; its salts; its esters and ethers; their salts IA
Levorphanol tartrate IA
Lofentanil; its stereoisomers; its salts its esters and ethers; their salts IA
Loprazolam mesylate IC
Lorazepam IC
Lormetazepam IC
Mazindol IB
Mecloqualone 1A
Medazepam IC
Mefenorex; its salts; its stereoisomers; their salts IB
Meperedine see Pethidine
Mephenamine; its salts IB
Mephen termine sulphate IB
Meprobamate IC
Metazocine; its salts; its esters and ethers; their salts 1A
Methadone; its salts 1A
Methadone hydrochloride 1A
Methadyl acetate; its salts 1A
Methamphetamine see Methylamphetamine
Methylamphetamine; its salts 1A
Methylamphetamine hydrochloride 1A
C.3S6

Methyldesorphine; its salts; its esters and ethers; their salts 1A
Methyldihydromorphone; its salts; its esters and ethers; their salts 1A
Methyldihydraorphonine see Metopon
2-Methyl-3-moipholo-1,1-diphenyl-propanecarboxylic acid; its salts;
its esters and ethers; their salts 1A
alpha-methylphenethyiamine see Amphetamine
N- (2-(N-methylphenethylamino)propyl)propionanilide see Diampromide
Methylphenidate; its salts 1A
Methylphenidate hydrochloride 1A
Methylphenobarbitone 1C
l-methyl-4-phenylpiperidine-4-carboxylic
acid; its salts; its esters and ethers; their salts 1A
Methyprylon 1C
Metopon; its salts; its esters and ethers; their salts 1A
Midazolam 1C
Morpheridine; its salts 1A
Morphine; its salts; its esters and ethers; their salts; its pentavalent nitrogen
derivatives; their esters and ethers 1A
Morphine acetate see Morphine
Morphine hydrochloride see Morphine
Morphine methobromide; its esters and ethers 1A
Morphine-N-oxide; its esters and ethers 1A
Morphine sulphate see Morphine
Morphine tartrate see Morphine
Morpholinoethylmorphethidine see Morpheridine
Myrophine; its salts 1A
Nicocodeine; its salts 1A
but if for non parenteral use and:
(a) in undivided preparations with ms 2.5% (calculated as base: Schedule 2) ID
(b) in single dose preparations with ms per dosage unit 1Omg
(calculated as base: Schedule 2) ID
Nicodicodeine; its salts 1A
but if for non-parenteral use and:
(a) in undivided preparations with ms 2.5% (calculated as base: Schedule 2) ID
(b) in single dose preparations with ms per dosage unit 1Omg (calculated
as base: Schedule 2) ID
Nicomorphine; its salts 1A
Nimetazepam 1C
Nitrazepam 1C
Noracymethadol; its salts 1A
Nordazepam 1C
Norcodeine; its salts 1A
but if for non-parenteral use and:
(a) in undivided preparations with ms 2.5% (calculated as base: Schedule 2) ID
(b) in single dose preparations with ms per dosage unit 1Omg (calculated
as base: Schedule 2) ID
Norlevorphanol; its salts; its esters and ethers; their salts 1A
Norme,hadone; its salts 1A
Normorphine; its salts; its esters and ethers; their salts 1A
Norpipanone; its salts 1A
Opium, medicinal 1A
<table>
<thead>
<tr>
<th>Compound</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxazepam</td>
<td>1C</td>
</tr>
<tr>
<td>Oxazolam</td>
<td>1C</td>
</tr>
<tr>
<td>Oxycodone; its salts; its esters and ethers; their salts</td>
<td>1A</td>
</tr>
<tr>
<td>Oxymorphone; its salts; its esters and ethers; their salts</td>
<td>1A</td>
</tr>
<tr>
<td>Papaveretum see Opium, medicinal</td>
<td></td>
</tr>
<tr>
<td>Pemoline</td>
<td>IB</td>
</tr>
<tr>
<td>Pentazbcine hydrochloride</td>
<td>IB</td>
</tr>
<tr>
<td>Pentazocine lactate</td>
<td>IB</td>
</tr>
<tr>
<td>Pentobarbitone</td>
<td>IB</td>
</tr>
<tr>
<td>Pentobarbitone sodium</td>
<td>IB</td>
</tr>
<tr>
<td>Pethidine; its salts</td>
<td>1A</td>
</tr>
<tr>
<td>Pethidine hydrochloride</td>
<td>1A</td>
</tr>
<tr>
<td>Phenadone see Methadone</td>
<td></td>
</tr>
<tr>
<td>Phenadoxone; its salts</td>
<td>1A</td>
</tr>
<tr>
<td>Phenampromide; its salts</td>
<td>1A</td>
</tr>
<tr>
<td>Phenazocine; its salts; its esters and ethers; their salts</td>
<td>1A</td>
</tr>
<tr>
<td>Phenazocine hydrobromide</td>
<td>IB</td>
</tr>
<tr>
<td>Phenmetrazine; its salts</td>
<td>1A</td>
</tr>
<tr>
<td>Phenmetrazine tartrate</td>
<td></td>
</tr>
<tr>
<td>Phenmetrazine; its salts</td>
<td>1A</td>
</tr>
<tr>
<td>Phenmetrazine hydrochloride</td>
<td>1A</td>
</tr>
<tr>
<td>Phenmetrazine theoclate</td>
<td>1A</td>
</tr>
<tr>
<td>Phenobarbitone</td>
<td>1C</td>
</tr>
<tr>
<td>Phenobarbitone sodium</td>
<td>1C</td>
</tr>
<tr>
<td>Phenomorphan; its salts; its esters and ethers; their salts</td>
<td>1A</td>
</tr>
<tr>
<td>Phenoperidine; its salts; its esters and ethers; their salts</td>
<td>1A</td>
</tr>
<tr>
<td>Phentermine</td>
<td>IB</td>
</tr>
<tr>
<td>Phenylmethylbarbituric acid</td>
<td></td>
</tr>
<tr>
<td>4-Phenylpiperidine-4-carboxylic acid ethyl ester; its salts</td>
<td>1A</td>
</tr>
<tr>
<td>Pholcodine; its salts</td>
<td>1A</td>
</tr>
<tr>
<td>but if for non-parenteral use and</td>
<td></td>
</tr>
<tr>
<td>(a) in undivided preparations with ms 2.5% (calculated as base: Schedule 2)</td>
<td>ID</td>
</tr>
<tr>
<td>(b) in undivided preparations with ms 1.5% (calculated as base) and md 20mg (calculated as base: Schedule 3)</td>
<td>ID</td>
</tr>
<tr>
<td>(c) in single-dose preparations with ms per dosage unit 100mg (calculated as base: Schedule 2)</td>
<td>ID</td>
</tr>
<tr>
<td>(d) in single-dose preparations with ms per dosage unit 1.5% (calculated as base) and md 20mg (calculated as base: Schedule 3)</td>
<td>ID</td>
</tr>
<tr>
<td>Pholcodine citrate see Pholcodine</td>
<td></td>
</tr>
<tr>
<td>Pholcodine tartrate see Pholcodine</td>
<td></td>
</tr>
<tr>
<td>Piminodine; its salts</td>
<td>1A</td>
</tr>
<tr>
<td>Pinazepam</td>
<td>1C</td>
</tr>
<tr>
<td>Ppipradroii; its salts</td>
<td>IB</td>
</tr>
<tr>
<td>Ppipradrol hydrochloride</td>
<td>IB</td>
</tr>
<tr>
<td>Piriramid; its salts</td>
<td>1A</td>
</tr>
<tr>
<td>Potassium clorazepe</td>
<td>1C</td>
</tr>
<tr>
<td>Prazezap</td>
<td>1C</td>
</tr>
<tr>
<td>Proheptazine; its salts</td>
<td>1A</td>
</tr>
<tr>
<td>Properidine; its salts</td>
<td>1A</td>
</tr>
<tr>
<td>Propiram; its salts</td>
<td>1A</td>
</tr>
</tbody>
</table>
but if in preparations containing, per dosage unit, not more than 100mg propiram (calculated as base, and compounded with at least same amount of methylcellulose: Schedule 2) ID
Propylhexedrine; its salts; its stereoisomers; their salts IC
Pyrovalerone; its salts; its stereoisomers; their salts IC
Quinalbarbitone IA
Quinalbarbitone sodium IA
Racemethorphan; its salts IA
Racemoramide; its salts IA
Racemorphinan; its salts; its esters and ethers; their salts IA
Secbutobarbitone IC
Secbutobarbitone sodium IC
Secobarbitone see Quinalbarbitone IC
Sufentanil; its salts; its esters and ethers; their salts IA
Temazepam IC
Thebano; its salts IA
Thebaine; its salts IA
Tilidate; its salts; its esters and ethers; their salts IA
Triazolam IC
Trimeperidine; its salts IA
Vinylbital IC
Acebutolol
Acepromazine
Acepromazine maleate
Acetanilide
Acetarsol
Acetazolamide
Acetazolamide sodium
Acetohexamide
Acetylcrombromaj
Acetylcysteine
Adreneline hydrochloride
Adrenaline acid tartrate
Adicillin
Acyclovir
Actinomycin C
Acetylsulphafurazole
Acetylsalicylic acid label (1)
Acetylstrophanthinid
Acetylsulphafurazolid
Acetylsulphamethoxypyridazine
Aconite
Acros oxacin
Actinomycin C
Actinomycin D
Acyclovir
Adicillin
Adiphenine hydrochloride
Adrenaline
Adrenaline acid tartrate
Adrenaline hydrochloride
Alkamide
Albumin human (immuno)
Acelofenac
Aclometasone dipropionate
Acuronium chloride
Aldosterone
Alfacalcidol
Algester acetoneid
Algester acetophenide
Allopurinol
Allyloestrenol
Alphadofone acetate
Alphaxalone
Alprehonol
Alrenchol hydrochloride
Alprostadil
Alsfoxylon
Altizide
Amantadine hydrochloride
Ambenonimum chloride
Ambuside
Ambutonium bromide
Amcinonide
Ametazone hydrochloride
Amethocaine
Amethocaine gentisate
Amethocaine hydrochloride
Amidopyridone
Amikacin sulphate
Aminolide hydrochloride
Aminocapric acid
Aminodarone hydrochloride
Aminogluthethemide
Aminophylline
Aminopterin sodium
Aminosalicylic acid
Amphenazone hydrochloride
Amitriptyline
Amitriptyline embonate
Amitriptyline hydrochloride
Ammonium bromide
Amodiaquine hydrochloride
Amoxapine
Amoxycillin
Amoxycillin trihydrate
Amphomycin
Amphetamine
Ampicillin
Ampicillin sodium
Ampicillin trihydrate
Amsacrine
Amylocaine hydrochloride
Ancrod
Androsterone
Angiotensin amide
Anterior pituitary extract
Antimony barium tartrate
Antimony dimercaptosuccinate
Antimony lithium thiomalate
Antimony pentasulphide
Antimony potassium tartrate
Antimony sodium tartrate
Antimony sodium thioglycollate
Antimony sulphate
Antimony trichloride
Antimony trioxide
Antimony trisulphide
Apiool
Apomorphine
Apomorphine hydrochloride
Apramycin
Apramycin sulphate
<table>
<thead>
<tr>
<th>Aprogin</th>
<th>Benzocaine hydrochloride</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arecoline</td>
<td>Benzoil peroxide</td>
</tr>
<tr>
<td>Arecoline-acetarsol</td>
<td>N-Benzoyl sulphanilamide</td>
</tr>
<tr>
<td>Arecoline hydrobromide</td>
<td>Benzquinarimide</td>
</tr>
<tr>
<td>Arsanilic acid</td>
<td>Benzquinarimide hydrochloride</td>
</tr>
<tr>
<td>Arsenic</td>
<td>Benzthiazide</td>
</tr>
<tr>
<td>Arsenic triiodide</td>
<td>Benztpine mesylate</td>
</tr>
<tr>
<td>Arsenic trioxide</td>
<td>Benzy1 penicillin</td>
</tr>
<tr>
<td>Arsphenamine</td>
<td>Benzyl penicillin calcium</td>
</tr>
<tr>
<td>Aspirin see acetylsalicylic acid</td>
<td>Betahistine hydrochloride</td>
</tr>
<tr>
<td>Astemizole</td>
<td>Betamethasone</td>
</tr>
<tr>
<td>Atenolol</td>
<td>Betamethasone adamantoate</td>
</tr>
<tr>
<td>Atracurium besylate</td>
<td>Betamethasone benzoate</td>
</tr>
<tr>
<td>Atropine</td>
<td>Betamethasone dipropionate</td>
</tr>
<tr>
<td>Atropine methobromide</td>
<td>Betamethasone sodium phosphate</td>
</tr>
<tr>
<td>Atropine methonitrate</td>
<td>Betamethasone valerate</td>
</tr>
<tr>
<td>Atropine oxide hydrochloride</td>
<td>Betaxolol hydrochloride</td>
</tr>
<tr>
<td>Atropine sulphate</td>
<td>Bethanecol chloride</td>
</tr>
<tr>
<td>Azacyclonol</td>
<td>Bethanidine sulphate</td>
</tr>
<tr>
<td>Azacyclonol hydrochloride</td>
<td>Biperidine hydrochloride</td>
</tr>
<tr>
<td>Azaperone</td>
<td>Biperidine lactate</td>
</tr>
<tr>
<td>Azapropazone</td>
<td>Bismuth glucoxylnalansilate</td>
</tr>
<tr>
<td>Azathioprine</td>
<td>Bleomycin sulphate</td>
</tr>
<tr>
<td>Azathioprine sodium</td>
<td>Boldenone undecylenate</td>
</tr>
<tr>
<td>Azidocillin potassium</td>
<td>Bretylum toslyate</td>
</tr>
<tr>
<td>Bacampicillin hydrochloride</td>
<td>Bromhexine hydrochloride</td>
</tr>
<tr>
<td>Bacitracin</td>
<td>Bromocriptine mesylate</td>
</tr>
<tr>
<td>Bacitracin methylene</td>
<td>Bromperidol</td>
</tr>
<tr>
<td>disalicylate</td>
<td>Bromvalentone</td>
</tr>
<tr>
<td>Bacitracin zinc</td>
<td>Budesonide</td>
</tr>
<tr>
<td>Baclofen</td>
<td>Bumetadine</td>
</tr>
<tr>
<td>Barium carbamate</td>
<td>Buphenine hydrochloride</td>
</tr>
<tr>
<td>Barium chloride</td>
<td>Bupivacaine</td>
</tr>
<tr>
<td>Barium sulphide</td>
<td>Bupivicaine hydrochloride</td>
</tr>
<tr>
<td>Beclamide</td>
<td>Buspirone hydrochloride</td>
</tr>
<tr>
<td>Beclomethasone</td>
<td>Busulphan</td>
</tr>
<tr>
<td>Beclomethasone dipropionate</td>
<td>Butacaine sulphate</td>
</tr>
<tr>
<td>Belladonna herb</td>
<td>Butamicaine phosphate</td>
</tr>
<tr>
<td>Belladonna root</td>
<td>Butriptyline hydrochloride</td>
</tr>
<tr>
<td>Bemegride</td>
<td>Butyrylcholyl hydrate</td>
</tr>
<tr>
<td>Benactyzine hydrochloride</td>
<td>Calcitonin</td>
</tr>
<tr>
<td>Benapryzine hydrochloride</td>
<td>Calcitriol</td>
</tr>
<tr>
<td>Bendroflauzide</td>
<td>Calcium aminosalicylate</td>
</tr>
<tr>
<td>Benethamine penicillin</td>
<td>Calcium amphomycin</td>
</tr>
<tr>
<td>Benoxaprofen</td>
<td>Calcium benzamidosalicylate</td>
</tr>
<tr>
<td>Benperidol</td>
<td>Calcium bromide</td>
</tr>
<tr>
<td>Benserazide</td>
<td>Calcium bromidoactobionate</td>
</tr>
<tr>
<td>Benza thine penicillin</td>
<td>Calcium carbimide</td>
</tr>
<tr>
<td>Benzbramaron</td>
<td>Calcium folicate</td>
</tr>
<tr>
<td>Benzhexol hydrochloride</td>
<td>Calcium metrizoate</td>
</tr>
<tr>
<td>Benzilonium bromide</td>
<td>Calcium sulphaloxate</td>
</tr>
<tr>
<td>Benzocaine</td>
<td></td>
</tr>
</tbody>
</table>
Candididin
Canrenonic acid
Cantharidin
Caphreomycin sulphate
Captopril
Caramiphen hydrosolide
Caramiphen edisylate
Carbachol
Carbamazepine
Carbenicillin sodium
Carbenoxolone sodium
Carbodopa
Carbidopa monohydrate
Carbimazole
Carbocisine
Carbon tetrachloride
Carboprost trometamol
Carbuterol
hydrochloride
Carbromal
Carindacillin sodium
Carisoprodol
Carmustine
Cefaclor
Cefazedone sodium
Geoxitin sodium
Ceftazidine
Cefuroxime sodium
Cefuroxime sodium
Cephalaxin
Cephalaxin sodium
Cephaloridine
Cephalosporin C
Cephalosporin E
Cephalosporin N
Cephalothin sodium
Cephamandole nafate
Cephazolin sodium
Cephradine
Cerium oxalate
Cetirizine
Chedodeoxycholic acid
Chloral antipyrine
Chloral beaiane
Chloral formamide
Chloral glycerolate
Chloral hydrate
Chloralose
Chloral urethene
Chlorambucil
Chloramphenicol
Chloramphenicol cinnamate
Chloramphenicol palmitate
Chloramphenicol sodium succinate
Chlorisondamine chloride
Chlormadinone acetate
Chlormerodrin
Chloromethazol
Chlormethazol edisylate
Chloromethane
Chloroform
Chloroquine phosphate
Chloroquine sulphate
Chlorothiazide
Chlorotrianisene
Chlorphenoxamine hydrochloride
Chlornpromazine
Chlorpromazine embonate
Chlorpromazine hydrochloride
Chlorpropamide
Chlorprothixene
Chlorprothixene hydrochloride
Chlortetracycline
Chlortetracycline hydrochloride
Chlorthalidone
Chloroxazone
Cholestemamine
Chorionic gonadotrophin
Ciclocloril
Ciclobendazole
Cimetidine
Cimetidine hydrochloride
Cinchocaine
Cinhochaine hydrochloride
Cinchophan
Cinnarizine
Cinoxin
Ciprofloxacine
Ciproiloxacin hydrochloride
Clavulanic acid
Clenbuterol hydrochloride
Clindinium bromide
Clindamycin
Clindamycin hydrochloride hydrate
Clindamycin palmitate
Clindamycin hydrochloride
Clindamycin phosphate
Chloquinol
Clodaticol 17-propionate
Clodetacone butyrate
Clofazimine
Clofibrate
Clomiphen citrate
Clomipramine
Clomipramine hydrochloride  
Clomocycline  
Clomocycline sodium  
Clonidine  
Clonidine hydrochloride  
Clopenthixol decanoate  
Clopenthixol hydrochloride  
Cloprostenol sodium  
Clorexolone  
Clorprenaline hydrochloride  
Clostebol acetate  
Clotrimazole  
Cloxacillin benzathine  
Cloxacillin sodium  
Cocculus indicus  
Co-dergocrine myselate  
Colchicine  
Colestipol hydrochloride  
Colistin sulphate  
Colistin sulphomethate  
Colistin sulphomethate sodium  
Conium leaf  
Corticotrophin  
Cortisone  
Cortisone acetate  
Cotarnine chloride  
Co-tetroxazine  
Co-trimoxazole  
Cropropamide  
Crotethamide  
Croton oil  
Croton seed  
Curare  
Cyclophosphamide  
Cyclophosphorin  
Cyclothiazide  
Cyproterone acetate  
Cytarabine  
Cytaombine hydrochloride  
Dacarbazine  
Danazol  
Dantrolene sodium  
Dapsone  
Dapsone ethane ortho sulphonate  
Daunorubicin hydrochloride  
Deanol salts and esters  
Debrisoquine sulphate  
Dehydroemetine hydrochloride  
Delmadinone acetate  
Demecarium bromide  
Demeclocycline  
Demeclocycline calcium  
Demeclocycline hydrochloride  
Deoxycortone acetate  
Deoxycortone pivalate  
Deptropine citrate  
Dequalinium chloride  
Deserpidine  
Desferroxamine mesylate  
Desfluorotriamcinolone  
Desipramine hydrochloride  
Deslanoside  
Desmopressin  
Desonide  
Desoxymethasone  
Dexamethasone  
Dexamethasone 21-isonicotinate  
Dexamethasone phenylpropionate  
Dexamethasone pivalate  
Dexamethasone sodium phosphate  
Dexamethasone sodium p-sulphobenzoate  
Dexamethasone trioxaundecanoate  
Dextromethorphan hydrobromide  
Dextrothyroxine sodium  
Diazoxide  
Dibenzepin hydrochloride  
Dichloralphenazone  
Dichloroprophylamine hydrochloride  
Dichlorphenamide  
Diclofenac sodium  
Dicyclomine hydrochloride  
Dienoestrol  
Diethanolamine fusidate  
Diethylamine acetarsol  
Difluorotoluol valerate  
Diflunisal  
Digitalis leaf  
Digi toxin  
Digoxin  
Dihydralazine sulphate  
Dihydroergotamine mesylate  
Dihydrostreptomycin sulphate  
Diltiazem hydrochloride  
Dimercaprol  
Dimethisouquin hydrochloride  
Dimethisterone  
Dimethothiazine mesylate  
Dimethyl sulphoxide  
Dimethylytubocurarine bromide  
Dimethylytubocurarine chloride
<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Drug Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dimethyltubocurarine iodide</td>
<td>Erythromycin</td>
</tr>
<tr>
<td>Dinitrodiphenylsulphonylethylenediamine</td>
<td>Erythromycin estolate</td>
</tr>
<tr>
<td>Dinoprost</td>
<td>Erythromycin ethyl carbonate</td>
</tr>
<tr>
<td>Dinoprostone</td>
<td>Erythromycin ethyl succinate</td>
</tr>
<tr>
<td>Diphenylarsine</td>
<td>Erythromycin lactobionate</td>
</tr>
<tr>
<td>Dipivefrin hydrochloride</td>
<td>Erythromycin phosphate</td>
</tr>
<tr>
<td>Diprenorphine hydrochloride</td>
<td>Erythromycin stearate</td>
</tr>
<tr>
<td>Dipyramidol</td>
<td>Erythromycin thiocyanate</td>
</tr>
<tr>
<td>Dipyrone</td>
<td>Estramustine phosphate</td>
</tr>
<tr>
<td>Disodium etidronate</td>
<td>Etafedrine hydrochloride</td>
</tr>
<tr>
<td>Disopyramide</td>
<td>Ethacrynic acid</td>
</tr>
<tr>
<td>Disopyramide phosphate</td>
<td>Ethamsylate</td>
</tr>
<tr>
<td>Distigmine bromide</td>
<td>Ethchlorvynol</td>
</tr>
<tr>
<td>Disulfiram</td>
<td>Ethbenecid</td>
</tr>
<tr>
<td>Disulphamide</td>
<td>Ethinylolastadiol</td>
</tr>
<tr>
<td>Dithranol</td>
<td>Ethionamide</td>
</tr>
<tr>
<td>Dobutamine hydrochloride</td>
<td>Ethisterone</td>
</tr>
<tr>
<td>Dompridone</td>
<td>Ethoheptazine citrate</td>
</tr>
<tr>
<td>Dopamine hydrochloride</td>
<td>Ethoprazine hydrochloride</td>
</tr>
<tr>
<td>Dothiepin</td>
<td>Ethosuximide</td>
</tr>
<tr>
<td>Dothiepin hydrochloride</td>
<td>Ethotoxin</td>
</tr>
<tr>
<td>Doxapram hydrochloride</td>
<td>Ethulose</td>
</tr>
<tr>
<td>Doxepin hydrochloride</td>
<td>Ethyl acetylanilide</td>
</tr>
<tr>
<td>Doxyccycline</td>
<td>Ethyl biscoumacetate</td>
</tr>
<tr>
<td>Doxyccycline calcium chelate</td>
<td>Ethylloestrenol</td>
</tr>
<tr>
<td>Doxyccycline hydrochloride</td>
<td>Ethynodiols diacetate</td>
</tr>
<tr>
<td>Droperidol</td>
<td>Etidronate dihydrochloride</td>
</tr>
<tr>
<td>Ddrostanolone</td>
<td>Etoptate</td>
</tr>
<tr>
<td>Drostanolone propionate</td>
<td>Factor XIII concentrate</td>
</tr>
<tr>
<td>Dyaxide</td>
<td>Fazadinium bromide</td>
</tr>
<tr>
<td>Dydrogesterone</td>
<td>Fenbufen</td>
</tr>
<tr>
<td>Econazole</td>
<td>Fenfluramine hydrochloride</td>
</tr>
<tr>
<td>Econazole nitrate</td>
<td>Fenoprofen</td>
</tr>
<tr>
<td>Ethiopate iodide</td>
<td>Fenoprofen calcium</td>
</tr>
<tr>
<td>Edrophonium</td>
<td>Fenoterol hydrobromide</td>
</tr>
<tr>
<td>Emepromium bromide</td>
<td>Fenpipramide hydrochloride</td>
</tr>
<tr>
<td>Emetine</td>
<td>Fenpiran hydrochloride</td>
</tr>
<tr>
<td>Emetine bismuth iodide</td>
<td>Ferrous arsenate</td>
</tr>
<tr>
<td>Emetine hydrochloride</td>
<td>Flavoxate hydrochloride</td>
</tr>
<tr>
<td>Enalapril maleate</td>
<td>Flecainide</td>
</tr>
<tr>
<td>Ephedrine</td>
<td>Fluanisone</td>
</tr>
<tr>
<td>Ephedrine hydrochloride</td>
<td>Flucloxacillin acetonide</td>
</tr>
<tr>
<td>Ephedrine sulphate</td>
<td>Flucloxacillin sodium</td>
</tr>
<tr>
<td>Epicilin</td>
<td>Flucytosine</td>
</tr>
<tr>
<td>Epirubicin</td>
<td>Fludrocortisone acetate</td>
</tr>
<tr>
<td>Epithiazide</td>
<td>Flufenamic acid</td>
</tr>
<tr>
<td>Epoprostenol sodium</td>
<td>Flugestone</td>
</tr>
<tr>
<td>Ergometrine maleate</td>
<td>Flugestone acetate</td>
</tr>
<tr>
<td>Ergometrine tartrate</td>
<td>Flumethasone</td>
</tr>
<tr>
<td>Ergotamine tartrate</td>
<td></td>
</tr>
<tr>
<td>Ergotoxin esylate</td>
<td></td>
</tr>
</tbody>
</table>
Flumethasone pivalate
Finnisolid
Fluocinolone acetonide
Fluocinonide
Fluocortiolone
Fluocortolone hexanoate
Fluocortolone pivalate
Flupromazine hydrochloride
Fluorouracil
Fluorouracil trometamol
Fluoxymesterone
Flupenthixol decanoate
Flupenthixol dihydrochloride
Fluperolone acetate
Fluphenazine deconoate
Fluphenazine enanthate
Fluphenazine hydrochloride
Fluprednidene acetate
Fluprednisolone
Fluprostenol sodium salt
Flurandrenolone
Flurbiprofen
Fluspirilene
Folic acid
Follicle stimulating hormone
Formosulphathiazole
Fosfostrol tetrasodium
Framycetin sulphate
Frusemide
Fumagillin
Fumagillin bicyclohexylamine
Furazolidone
Fusidic acid
Gallamine triethiodide
GelSense
Gelsemic acid
Gelfibrozil
Gentamicin
Gentamicin sulphate
Gestrone
Gestrone hexanoate
Glibenclamide
Glibornuride
Glilezide
Glipizide
Glucagon
Giyercyl trinitrate
Glycypyrromonium bromide
Glymidone
Gonadorelin
Gramicidin
Griseofulvin
Growth hormone
Guanethidine monosulphate
Guanoclor sulphate
Guanoxan sulphate
Hachimycin
Halcinonide
Haloperidol
Heparin
Heparin calcium
Heptaminol hydrochloride
Hexachlorophene
Hexamidine phenylcinchoninate
Hexoestrol
Hexoestrol dipropionate
L-Histidine hydrochloride
Homatropine
Homatropine hydrobromide
Homatropine methylbromide
Hydralazine hydrochloride
Hydargaphen
Hydrobromic acid
Hydrochlorothiazide
Hydrocortamate hydrochloride
Hydrocortisone
Hydrocortisone acetate
Hydrocortisone 17-butyrate
Hydrocortisone caprylate
Hydrocortisone hydrogen succinate
Hydrocortisone sodium phosphate
Hydrocortisone sodium succinate
Hydroflumethiazide
Hydroquinone
Hydroxychloroquine sulphate
1 alpha-Hydroxy calciferol
Hydroxymethylglucaminidin
4-Hydroxy-3-nitrophenylarsonic acid
Hydroxyprogesterone
Hydroxyprogesterone enanthate
Hydroxyprogesterone hexanoate
Hydroxyurea
Hydroxyzine embonate
Hydroxyzine hydrochloride
Hyoscine
Hyoscine butylbromide
Hyoscine hydrobromide
Hyoscine methobromide
Hyoscine methonitrate
Hyoscyamine
Hyoscyamine hydrobromide
Hyoscyamine sulphate
Ibuprofen
Iodoxuridine
Ignatius bean
Imipramine
Imipramine hydrochloride
Imipramine ion exchange resin
bound salt or complex
Indapamide hemihydrate
Indomethacin
Indoramin hydrochloride
Insulins
Iodamide
Iodamide meglumine
Iodamide sodium
Ipecacuanha see emetine
Ipratropium bromide
Iprindole hydrochloride
Iproniazid phosphate
Iron; its salts
Isoamimile
Isoamimile citrate
Isocarboxazid
Isoconazole nitrate
Isoetharine
Isoetharine hydrochloride
Isoetharine mesylate
Isoniazid
Isoprenaline hydrochloride
Isoprenaline sulphonate
Isopropamide iodide
Jabprondi.
Kanamycin sulphate
Ketamine hydrochloride
Ketoxazol
Ketoprofen
Ketotifen
Labetolol hydrochloride
Lactogemine hormone
Lanatoside C
Lanatoside complex A, B and C
Lamoxef disodium
Lead arsenate
Levallophan tartrate
Levodopa
Lidofozine
Lignocaine
Lignocaine hydrochloride
Lincomycin
Lincomycin hydrochloride
Liothyronine sodium
Lithium carbonate
Lithium sulphate
Lobelia; its salts
Lofepramine
Lofepramine hydrochloride
Lomustine
Loperamide hydrochloride
Loratadine
Loxapine succinate
Luteinising hormone
Lymeclycline
Lynoestrogen
Mafenide acetate
Mafenide hydrochloride
Mafenite propionate
Magnesium bromide
Magnesium fluoride
Magnesium metrizoate
Mandragara autumnalis
Mannomustine
hydrochloride
Maprotiline hydrochloride
Mcbeverine hydrochloride
Melbydroflin napadisylate
Mecamylamine
hydrochloride
Meclofenoxide
hydrochloride
Medroges trone
Medroxyprogesterone
acetate
Mefenamic acid
Mefruside
Megestrol
Megestrol acetate
Meglumine iodoxamate
Meglumine ioglycamate
Meglumine iotratex
Meglumine ioxaglate
Melarsonyl potassium
Mclengestrol
Melengestrol acetate
Melphalan
Mephalan hydrochloride
Mepenzolate bromide
Mephenesin
Mephenesin carbamate
Mepivacaine hydrochloride
Mepatuzinol hydrochloride
Mequitazine
Mercaptopurine
Mecureramide
Mersalyl
Mersalyl acid
Mesterolone
Metabutethamine
hydrochloride
Mepivacaine hydrochloride
Metoprolol tartrate
Mepenzolate bromide
Mephenesin
Mephenesin carbamate
Mepivacaine hydrochloride
Mepatuzinol hydrochloride
Mequitazine
Mercaptopurine
Mercureramide
Mersalyl
Mersaly acid
Mesterolone
Metabutethamine
Metaraminol tartrate
Metformin hydrochloride
Methacycline
Methacycline calcium
Methacycline hydrochloride
Methallenoestril
Methandienone
Methandriol
Methyldazine hydrochloride
Methenolone acetate
Methenolone enanthate
Methicillin sodium
Methimazole
Methimazole succinate
Methyloclothiazide
N-Methyl acetalidene
Methyldopa
Methyldopate hydrochloride
Methylephedrine hydrochloride
Methylergotamine maleate
Methylpentynol
Methylprenolol carbamate
Methylprednisolone acetate
Methylprednisolone sodium succinate
Methyltestosterone
Methylthiouracil
Methysergide maleate
Metoclopramide hydrochloride
Metolazone
Metomidate hydrochloride
Metoprolol tartrate
Metronidazole
Metronidazole benzoate
Mexiletine hydrochloride
Methylcellulose sodium
Mianserin hydrochloride
Miconazole
Miconazole nitrate
Minocycline
Minocycline hydrochloride
Minoxidil
Mithramycin
Mitomycin C
Mitopodizole
Mitoxantrone hydrochloride
Molindone hydrochloride
Mustine hydrochloride
Nadolol
Naftifidine oxalate
Nalbuphine hydrochloride
Nalidixic acid
Nalorphine hydrobromide
Naloxone hydrochloride
Nandrolone decanoate
Nandrolone laurate
Nandrolone phenylpropanoate
Naphazoline hydrochloride
Naphazoline nitrate
Naproxen
Naproxen sodium
Natamycin
Nedocromil sodium
Nefopam hydrochloride
Neosarphenamine
Neomycin
Neomycin palmitate
Neomycin sulphate
Neomycin undecanoate
Neostigmine bromide
Neostigmine methylsulphate
Netilmicin sulphate
Nialamide
Nicotinamide thiosalicylic acid
Nicoumalone
Nifedipine
Nikethamide
Nitidazole
Nitrofurantoin
Nitrofurazone
NNitrosoamphetamine
Nomifensine hydrogen maleate
Noradrenaline
Noradrenaline acid tartrate
Norestandrolone
Norethisterone
Northisterone acetate
Northisterone heptanoate
Norhexynodrel
Norgestrel
D-Norgestrel
Nortriptyline hydrochloride
Novobiocin calcium
Novobiocin sodium  Paraldehyde
Nystatin  Paramehadione
Oestradiol  Paramethasone acetate
Oestradiol benzanoate  Parathyroid gland
Oestradiol cypionate  Pargyline hydrochloride
Oestradiol dipropionate  Paromycin sulphate
Oestradiol diundecanoate  Pencolcin
Oestradiol enanthate  Pempidine tartrate
Oestradiol phenylpropionate  Penbutolol sulphate
Oestradiol undecanoate  Penethamate
Oestradiol vaierate  Penicillamine
Oestradiol di-hemisuccinate  Penicillin V
Oestrogenic substances,  Pentamidine
conjugated  Perhexiline hydrogen maleate
Oestriol  Pericyazine
Oestriol diundecanoate  Perphenazine
Oestriol di-hemisuccinate  Phenacaine
Oxybutynin  Phenacetin
Oxamniquine  Phenacemide
Oxandrolone  Phernasone suiphoxylate
Oxantel pamoate  Phenazone
Oxatomide  Phenazone salicylate
Oxederine tartrate  Phenbenicillin potassium
Oxolinic acid  Phebutrazate hydrochloride
Oxopharnasine hydrochloride  Phenelzine sulphate
Oxopharnasine tartrate  Phenethicillin potassium
Oxpentifyline  Phenetidine
Oxprenolol hydrochloride  Phenformine hydrochloride
Oxbuprocaine hydrochloride  Phenylbutazone
Oxybuprocaine hydrochloride  Phenol benzoate
potassium  Phenol benzoate sodium
Oxymeterone  Phenylephrine hydrochloride
Oxymetholone  Phenylpropanolamine
Oxyptine  hydrochloride
Oxypertine hydrochloride  hydrochloride
Oxyphencyclline hydrochloride  Phenyltoin
Oxyphencyclline hydrochloride  Phenyltoin sodium
Oxyphononium bromide  Phthalysulphacetamide
Oxytetacycline  Phthalysulphathiazole
Oxytetacycline calcium  Phystostigmine
Oxytetacycline dihydrate  Phystostigmine aminoxide
Oxytetracycline hydrochloride  salicylate
Oxytocins, natural and synthetic  Phystostigmine salicylate
Pancuronium bromide  Papaverine
Papaverine  Papaverine hydrochloride
Papaverline  Papaveroline
Papaveroline  Papaveroline 2-sulphonic acid
Physostigmine sulphate
Piloearpine
Pilocarpine hydrochloride
Piloearpine nitrate
Pimozide
Pindolol
Pipenzolate bromide
Piperacillin sodium
Piperazine oestrone sulphate
Piperidolate hydrochloride
Pipothazine palmitate
Piracetam
Piributerol acetate
Piributerol hydrochloride
Pirenzepine hydrochloride
Piracetam
Piroxicam
Pituitary gland (whole dried)
Pituitary powdered (posterior
globe)
Pivampicillin hydrochloride
Pivmecillinam
Pivmecillinam hydrochloride
Pizotifen
Pizotifen hydrogen maleate
Plicamycin
Podophyllum indian
Podophyllum resin
Poldine methylsulphate
Polidexide
Polidexide hydrochloride
Polidexide sulphate
Polymyxin B sulphate
Polyoestradiol phosphate
Polythiazide
Potassium aminosalicylate
Potassium arsenite
Potassium bromide
Potassium cancrenoate
Potassium chloride
Potassium citrate
Potassium clavulanate
Potassium perchlorate
Pralidoxime chloride
Pralidoxime iodide
Pralidoxime mesylate
Prazosin hydrochloride
Prednisolone
Prednisolone acetate
Prednisolone butylacetate
Prednisolone hexanoate
Prednisolone pivalate
Prednisolone sodium phosphate
Prednisolone sodium m-sulphobenzoate
Prednisolone 21-steaglate
Prednisolone m-sulphobenzoate
Prednisone
Prednisone acetate
Prenalterol hydrochloride
Prenylamine lactate
Prilocaine hydrochloride
Primaquine phosphate
Primodine
Probenecid
Prooocul
Procainamide hydrochloride
Procaine hydrochloride
Procaine penicillin
Procarbazine hydrochloride
Prochlorperazine edisylate
Prochlorperazine maleate
Prochlorperazine mesylate
Procyclidine hydrochloride
Progesterone
Proguanil hydrochloride
Prolintane hydrochloride
Promazine embonate
Promazine hydrochloride
Propanidid
Propantheline bromide
Propicillin potassium
Propiomazine hydrogen maleate
Propranolol hydrochloride
Propylthiouracil
Propylphenazone
Proquamezine fumarate
Proquazone
Prostaglandin F2 alpha tromethamine
Protamine sulphate
Prothionamide
Prothipendyl hydrochloride
Protrotriptyline hydrochloride
Proxymetacaine hydrochloride
Pseudoephedrine hydrochloride
Pseudoephedrine sulphate
Pyranetl embonate
Pyrantel tartrate
Pyrazin amide
Pyridostigmine bromide
Pyrimethamine
L-Pyroglutamyl-L-histidyl-L-proline
amide
Quines tradiol
Quincostrol
Quinethazone
Quingestanol
Quinidine
Quinidine bisulphate
Quinidine phenoxyethylbarbiturate
Quinidine polygalacturonate
Quinidine sulphate
Quinine; its salts
Quinuronic sulphate
Racemedrine hydrochloride
Rantidine hydrochloride
Rawolfia (serpetina and vomitória)
Reproterol hydrochloride
Rescinnamid
Reserpine
Rfamide
Rifampicin
Rifamycin
Rimicerol hydrobromide
Ritodrine hydrochloride
Rolitetracycline nitrate
Salazosulphadimidine
Salbutamol
Salbutamol sulphate
Selegiline hydrochloride
Se and antiser
Serum gonadotrophin
Silver sulphadiazine
Sissomycin sulphate
Sodium aminosalicylate
Sodium antimonylgluconate
Sodium apolate
Sodium arsenate
Sodium arsenite
Sodium bromate
Sodium bromide
Sodium cadoxylate
Sodium cromoglicate
Sodium ethacrylate
Sodium fluoride
Sodium fructosid
Sodium methylerusinate
Sodium metrizoate
Sodium monofluorophosphate
Sodium stibogluconate
Sodium valproate
Sotalol hydrochloride
Spectinomycin
Spiramycin
Spiramycin adipate
Spirinolactone
Sulfabromethazine
Sulfamonomethoxine
Sulconazole nitrate
Streptomycin sulphate
Stilboestrol
clotho
Streptomycin sulphate
Strychnine
Strychnine arsenate
Strychnine hydrochloride
S ucinylsulphathiazole
Sucralfate
Sulbactam sodium
Sulconazole nitrate
Sulfacytine
Sulfadecrimate
Sulfadoxine
Sulfame toprozine
Sulfamonomethoxine
Sulfapyrazole
Sulfabromethazine
Sulphacetamide
Sulphacetamide sodium
S sulphasulopyridazine
Sulphadiazine
Sulphadiazine sodium
Sulphadimethoxine
Sulphadimidine
Sulphadimidine sodium
Sulphafurazole
Sulphafurazole diethanolamine
S sulphaguanidine
Sulphaloxicacid
S sulphaermazine
Sulphamerazine sodium
S sulphamethizole
S sulphamethoxazole
S sulphamethoxydiazine
S sulphamethoxydipiridazine
Sulphamethoxypyridazine sodium
S u lphamethy Iphenazone
Sulphamoxole
Sulphanilamide
Sulphaphenazole
Sulphapyridine
Sulphapyridine sodium
Sulphaquinoxaline
Sulphaquinoxaline sodium
Sulpharsphenamine
Sulphasalazine
Sulphasomidine
Sulphasomidine sodium
Sulphathiazole
Sulphathiazole sodium
Sulphathiozole
Sulphaurea
Sulphinpyrazone
Sulphomycin
Sulpiride
Sulthiame
Suxamethonium bromide
Suxamethonium chloride
Suxethonium bromide
Tacrine hydrochloride
Talampicillin
Talampicillin hydrochloride
Talampicillin napsylate
Tamoxifen
tamoxifen citrate
Teclothiazide potassium
Terbutaline
Terbutaline sulphate
Testosterone
Testosterone acetate
Testosterone 17B chlGral hemiacetal
Testosterone cyclohexylpropionate
Testosterone cypionate
Testosterone decanoate
Testosterone enanthate
Testosterone isocaproate
Testosterone phenylpropionate
Testosterone propionate
Testosterone undecanoate
Tetrabenazine
Tetracosatin
tetracosatin acetate
Tetracycline
Tetracycline hydrochloride
Tetracycline phosphate complex
Thallium acetate
Theophylline
Thiabendazole
Thiethylperazine
Thiethylperazine di-(hydrogen malate)
Thiocarlide
Thioguanine
Thiopentone sodium
Thiopropazate hydrochloride
Thioproperazine mesylate

Thioridazine
Thioridazine hydrochloride
Thiotepa
Thiohexene
Thiouracil
Thymoxaraine hydrochloride
Thyroid
Thyrotrophin
Thyrotrophin releasing hormone
Thyroxine sodium
Tianulin hydrogen fumarate
Tiaprofenic acid
Ticarcillin sodium
Tigloidine hydrobromide
Timolol maleate
Tinidazole
Tioconazole
Tobramycin
Tobramycin sulphate
Tocainide hydrochloride
Toferiacin hydrochloride
Tolazamide
Tolazoline hydrochloride
Tolbutamide
Tolbutamide sodium
Tolmetin sodium dihydrate
Tolperisone
Totaquine
Tranexamic acid
Tranylcypromine sulphate
Trazadone
Tresulfan
Tretamine
Tretinoin
Triacetyloleandomycin
Triamcinolone
Triamcinolone acetonide
Triamcinolone diacetate
Triamcinolone hexacetonide
Triamterene
Tribromo ethyl alcohol
Triclofos sodium
Tricyclamol chloride
Trienbolone acetate
TrienLine dihydrochloride
Trifluoperazine
Trifluoperazine hydrochloride
Trifluoperidol
Trifluoperidol hydrochloride
Trilostane
Trimeprazine
Trimetazine tartrate  
Trimetaphan camsylate  
Trimetazidine  
Trimetazidine hydrochloride  
Trimethoprim  
Trimipramine maleate  
Trimipramine mesylate  
Trimustine hydrochloride  
Tripolidine  
Tropicamide  
L-Tryptophan  
Tubocurarine chloride  
Tybamate  
Tylosin  
Tylosin phosphate  
Tylosin tartrate  
Tyrothricin  
Uramustine  
Urea stibamine  
Uridine-5-triphosphoric acid  
Urifollitrophin  
Urokinase  
Ursodeoxycholic acid  
Vaccines  
Valproic acid  
Vancomycin hydrochloride  
Vasopressin tannate  
Vecuronium bromide  
Verapamil hydrochloride  
Viloxazine hydrochloride  
Vinblastine sulphate  
Vincristine sulphate  
Vindesin sulphate  
Viomycin pantothenate  
Viomycin sulphate  
Vitamin A  
Vitamin A acetate  
Vitamin a palmitate  
Vitamin D  
Vitamins  
Warfarin  
Warfarin sodium  
Xylazine hydrochloride  
Yohimbine hydrochloride  
Zidovudine  
Zinc sulphate in preparations for local ophthalmic use  
Zimeidine hydrochloride  
Zomepirc sodium  
Zuclopenthixol hydrochloride
(3) SCHEDULE 3 DRUGS

Acetazolamide in preparations for external use
Acetylsalicylic acid in preparations with nd 500mg and not more than 30 doses, (except those intended for children under 12 years: Schedule 2).

label (1)
Aconite in preparations and mixtures of ms 9.02%
Adrenaline, if
(a) in inhalers
(b) in preparations for external use
Amethocaine in preparations for non-parenteral use, (except those intended for local ophthalmic use: Schedule 2).
Amethocaine gentisate in preparations for non-parenteral use (except those intended for local ophthalmic use: Schedule 2).
Amethocaine hydrochloride in preparations for non-parenteral use, (except those intended for local ophthalmic use: Schedule 2).
Astemizole in preparations licensed and labelled for the treatment of hay fever in adults and children over 12 years.

label (5)
Airopine in preparations for external use, (except those intended for local ophthalmic use: Schedule 2)
Airopine methobromide in preparations for external use, (except those intended for local ophthalmic use: Schedule 2)
Airopine methonitrate in preparations for external use, (except those intended for local ophthalmic use: Schedule 2)
Atropine oxide hydrochloride in preparations for external use, (except those for -local ophthalmic use: Schedule 2)
Azadine maleate

label (5)
Benzocaine in preparations for non-parenteral use (except those for local ophthalmic use: Schedule 2)
Benzoyleperoxide in preparations for external use with ms 10%
Boric acid
Brompheniramime maleate
Bupivacaine in preparations for non-parenteral use, (except those intended for local ophthalmic use: Schedule 2)
Bupivacaine hydrochloride in preparations for non-parenteral use, (except those intended for local ophthalmic use: Schedule 2)
Butacaine sulphate in preparations for non-parenteral use, (except those intended for local ophthalmic use: Schedule 2)
Butanilicaine phosphate in preparations for non-parenteral use, (except preparations intended for local ophthalmic use: Schedule 2)
Caffeine
Cantharidin in preparations for external use and ms 0.01%
Caramiphen edisylate in:
(a) tablet preparations and ins 7.5mg (calculated as base)
(b) liquid preparations and ms 0.1% (calculated as base)
Carbenoxolone sodium in preparations for external use ms 2%
Chlorhexidine
Chloroquine phosphate for prophylaxis of malaria.
Labelling for malaria prophylaxis
Chloroquine sulphate for prophylaxis of malaria.
  Labelling for malaria prophylaxis
Chlorpheniramine maleate, label (5)
  (But in preparations for parenteral use: Schedule 2)
Cinchocaine in preparations for non-parenteral use and ms 3%, (except preparations for local
ophthalmic use: Schedule 2)
Cinchocaine hydrochloride in preparations for non-parenteral use hIS 3%, (except
preparations for local ophthalmic use: Schedule 2)
Clemastine, label (5)
Clioquinol in preparations for external use
Clotrimazole in preparations for external use
Cyclizine hydrochloride in preparations for non-parenteral use
Dequalinium chloride in:
  (a) throat lozenges or throat pastilles and ms 0.25mg
  (b) external paint preparations and ins 1%
Dextromethorphan hydrobromide in preparations for intrrenal use with md 15mg (calculated
as base)
Diclofenac in preparations for external use
Dicyclomine hydrochloride in non-parenteral
preparations, label (6)
Dimenhydrinate in preparations for non-parenteral use
  label (5)
Dimethindine maleate, label (5)
Dimethisooquin hydrochloride in preparations for non-parenteral use, (except preparations for
local ophthalmic use: Schedule 2)
Diphenhydramine hydrochloride in preparations for non-parenteral use, label (5).
Diphenylpyraline hydrochloride, label (5)
Econazole in preparations for external use, (except for vaginal use: Schedule 2)
Econazole nitrate in preparations for external use, (except for vaginal use: Schedule 2)
Emetine in preparations for internal or external use and ms 1%
  . Emetine hydrochloride in preparations for internal or external use and ms 1% (calculated as
  base)
Ephedrine in:
  (a) preparations for internal use (except nasal sprays or nasal drops) with Bid 30mg and
      mdâ 60mg, label (4)
  (b) nasal sprays or nasal drops and ms 2%
      label (4)
Ephedrine hydrochloride in:
  (a) preparations for internal use (except nasal sprays and nasal drops) with ms 30mg.g
      (calculated as base) and xndd 60m2 (calculated as base)
      label (4)
  (b) nasal sprays or nasal drops and ms 2% (calculated as base), label (4)
Folk acid (schedule 2) in preparations for internal use and mdd 500 micrograms,
Gramicidin in preparations for external use and ms 0.02%
Hexachlorophene in preparations for external use and:
  (a) in soaps with ms more than 0.1% but not more than 2%
      label (6)
  (b) in products other than soacs or aerosols with ms more than 0.1% but not more than
      0.75%
      label (6)
L-Histidine hydrochloride used as an ingredient in
dietary or nutritional products as an amino acid
Homatropine in preparations for external use (except preparations for local ODthalmic use: Schedule 2)
Hydroxychloroquine sulphate for the prophylaxis of malaria
  Labelling for malaria prophylaxis
Hydrocortisone in preparations for external use and ms 1 %
Hydroxyethylgramicidin in throat lozenges or throat pastilles
Ibuprofen in preparation for internal use with ms 200mg and not more than 30 doses
Idoxuridine in preparations for external use (except preparations for local ophthalmic use: Schedule 2)
Indomethacin in preparations for external use
Isoconazole nitrate for external use, (except preparations intended for vaginal use:
  Schedule 2)
Lignocaine in preparations for non-parenteral use, (except those intended for local ophthalmic use: Schedule 2)
Lignocaine hydrochloride in preparations for non-parenteral use. (except those intended for
  local ophthalmic use: Schedule 2)
Mebendazole
Mepivacaine hydrochloride in preparations for non-parenteral use, (except those intended for
  local ophthalmic use: Schedule 2)
Metubutethamine hydrochloride in preparations for non-parenteral use, (except preparations for
  local ophthalmic use)
Methylephedrine hydrochloride in preparations for internal use with ms 3 Omg and mdd 60m g
Miconazole for external use (except vaginal use; Schedule 2)
Naphazoline hydrochloride:
  (a) in nasal sprays or nasal drops not containing liquid paraffin as vehicle and jns 0.05%
  (b) in eye drops and ms 0.015%
Naphazoline nitrate in nasal sprays or nasal drops not containing liquid paraffin as vehicle and
  ms 0.05%
Nitrofurazone in preparations for external use
Orthoacetin in preparations for non-parenteral use, (except those intended for local ophthalmic
  use: Schedule 2)
Oxybuprocaine hydrochloride in preparations for non-parenteral use, (except those intended for
  local ophthalmic use: Schedule 2)
Paracetamol
  label (3)
Phenacaine in preparations for non-parenteral use, (except those intended for local ophthalmic
  use)
Phenindamine tartrate
Pheniramone maleate
Phenolphthalein
Phenylephrine hydrochloride but if in eye drops with ms 10%
Phenylpropanolamine hydrochloride:
  (a) in preparations for internal use (except controlled release capsules, nasal sprays or nasal
      drops) with mdd 25mg and mdd IOOmg
  (b) in controlled release capsules with mdd 50mg and mdd IOQmg
  (c) in nasal sprays or nasal drops with ms of 2%
Piperazine
Ppdophylinium resin in ointments or impregnated plasters for external use with ms 20%
Prilocaine hydrochloride in preparations for non-parenteral use, (except those intended for
  local ophthalmic use: Schedule 2)
Procaine hydrochloride in preparations for non-parenteral use, (except those intended for local ophthalmic use: Schedule 2)
Proguanil hydrochloride for prophylaxis of malaria
   Labeling for malaria prophylaxis
Proxymetacaine hydrochloride in preparations for non-parenteral use (except those intended for local ophthalmic use: Schedule 2)
Pseudophedrine hydrochloride in preparations for internal use with md 60mg and mdd 180mg
Pseudophedrine sulphate in preparations for internal use with md 60mg and mdd 180mg
Quinine in preparations for internal use md 100mg (calculated as base) and mdd 300mg (calculated as base)
Sodium apolate in preparations for external use
Sodium arsenite in preparations for internal and external use and ms 0.013%
Sodium cromoglycate in preparations for use by being administered through the nose
Sodium fluoride:
   (a) in preparations for use in the prevention of dental caries, other than dentifrices, in the form of:
   (i) tablets or drops and mdd 2.2mg
   (ii) mouth rinses other than those for daily use and ms 0.2%
   (iii) mouth rinses for daily use and ms 0.05%
Streptodornase in preparations for external use
S Ixektozinase in preparations for external use
Sulconazole in preparations for external use, (except vaginal use Schedule 2)
Terfenadine
Thiabendazole in preparations for external use
Tioconazole in preparations for external use (except vaginal use: Schedule 2) with ms 2%
Tyrothricin in throat lozenges or throat pastilles
Zinc sulphate in non-parenteral preparations (except in preparations for local ophthalmic use: Schedule 2)
(4) **SCHEDULE 4 DRUGS**

Aluminium compounds
Ascorbic acid in preparations for non-parenteral use
Benzocaine in preparations for external use and ms 1% (except preparations for local ophthalmic use: Schedule 2)
Carbon tetrachloride
   N.B. if the unlicensed product is sold for non-medical purposes e.g. cleaning, there are no restrictions on its sale
Cetrimide
Chlorhexidine:
   (a) for external use (except vaginal use: Schedule 3)
   (b) in preparations for mouth wash and for use in the prevention of dental caries
Chloroform in liquid preparations for internal use and ms 0.5%
Folic acid in preparations for internal use and mdd 200 micrograms
Glycerol
Hexachlorophene:
   in preparations for external use and:
   (a) in soaps with ms 0.1%
       label (6)
   (b) in aerosols with ms 0.1%
       label (6)
   (c) in products other than soaps or aerosols with ms 0.1%
       label (6)
Iron in preparations for internal use and mdd 100mg (calculated as iron)
Lignocaine in preparations for external use and ms 0.6% (except preparations for local ophthalmic use: Schedule 2)
Lignocaine hydrochloride in preparations for external use and ms 0.7% (except preparations for local ophthalmic use: Schedule 2)
Magnesium trisilicate
Paracetamol in tablet preparations with ms 500mg and not more than 30 tablets
   label (3)
Sodium fluoride in dentifrices and ms 0.33%
Sodium monofluorophosphate in dentifrices and ms 1.14%
Stannous fluoride in dentifrices and ms 0.62%
Vitamin A in:
   (a) preparations for internal use with mdd 7500 iu Vitamin A (2250 meg Retinol equivalent)
   (b) preparations for external use
Vitamin A acetate in:
   (a) preparations for internal use with mdd equivalent to 7500 iu Vitamin A (2250 meg Retinol equivalent)
   (b) preparations for external use
Vitamin A palmitate in:
   (a) preparations for internal use with mdd equivalent to 7500 iu Vitamin A (2250 meg Retinol equivalent)
   (b) preparations for external use
Vitamin D in:
   (a) preparations for internal use with mdd 10 meg
   (b) preparations for external use
Vitamins, mixed in non-parenteral preparations
Explanation of abbreviations and other phrases used in lists of drugs

**md:** (maximum dose) i.e. the maximum quantity of the drug or substance that is contained in the amount of a medicinal product which is recommended to be taken or administered at any one time.

**mdd:** (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours.

**ms:** (maximum strength) i.e. either or, if so specified, both of the following:
  (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or
  (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w or v/v, as appropriate.

**external use:** means for application to the skin, teeth, mucosa of the mouth, throat, nose, eye, ear, vagina or anal canal when a local action only is necessary and extensive systemic absorption is unlikely to occur.

N.B. The following are not regarded as for external use: throat sprays, throat pastilles, throat lozenges, throat tablets, nasal drops, nasal sprays, nasal inhalations or teething preparations.

**oral use:** means administration through the mouth.

**parenteral administration:** means administration by breach of the skin or mucous membrane.
SECOND SCHEDULE  (reg. 21)

Amphetamine
Bromamphetamine (DOB, Bromo-SP)
Bufotenine(N,N-Dimethylserotonin)
Cannabis
Cocaine
Coca Leaf
Cathinone
DET or 3-[2-(diethylamino)ethyl]indole
Dexamphetamine
DMA or (+ or -)-2,5-dimethoxy-alpha-methylphenethylamine
DMT or 3-[2-(dimethylamino)ethyl]indole
DOET or (+ or -)-4-ethyl-2,5-dimethoxy-alpha-phenethylamine
Egonine
Eticyclidine (PCE)
Fentanyl analogues (unless listed in another Schedule):
  acetyl-alpha-methyl-fentanyl
  alpha-methyl-fentanyl
  alpha-methyl-fentanyl-acetanilide
  alpha-methyl-thiofentanyl
  beta-hydroxy-fentanyl
  3-methyl-thiofentanyl
  3-methyl-fentanyl and its cis- and trans- isomeric forms
  thiofentanyl
  para-fluoro-fentanyl
Harmaline
Harmine
Heroin (diacetylmorphine)
(+)-lysergide (LSD, LSD-25)
MDMA or (+ or -)-N, alpha-dimethyl-3,4-(methylenedioxy)-phenethylamine
Mecloqualone
Mescaline
Methaqualone
4-methylaminorex
MMDA or 2-methoxy-alpha-methyl-4,5(methylenedioxy)phenethylamine
N-ethyl MDA or (+ or -)-N-ethyl-alpha-methyl-3,4-(methylenedioxy)phenethylamine
N-hydroxy MDA or (+ or -)-N-[alpha-methyl-3,4(methylene-dioxy)phenethyl]hydroxylamine
Opium
Parahexyl
Pethidine analogues:
  l-methyl-4-phenyl-4-propionoxy-piperidine (MPPP)
  l-methyl-4-phenyl-2,5,6-tetrahydropieridine (MPTP)
  l-phenylethyl-4-phenyl-4-acetyloxy-piperidine (PEPAP)
PMA
Poppy straw concentrate
Psilocine or psilotin
Psilocybine
Rolicyclidine (PHP, PCPY)
STP, DOM or 2,5-dimethoxy-alpha,4-dimethylphenethylamine
Tenamfetamine (MDA)
Tenocyclidine (TCP)
Tetrahydrocannabinol
TMA or (+ or -)-3,4,5-trimethoxy-alpha-methylphenethylamine

All preparations and mixtures of the following unless specifically excluded or unless listed in another Schedule:

(i) the isomers of substances above, where existence of such isomers is possible;
(ii) the esters and ethers of such substances and of the isomers referred to above or isomers of such esters and ethers, where the existence of such esters, ethers and isomers is possible;
(iii) the salts of such substances and of the isomers referred to in (i), and the salts of the esters, ethers and isomers referred to in (ii), where the existence of such salts is possible;
(iv) the isomers of any of the salts referred to in (iii), where the existence of such isomers is possible.

THIRD SCHEDULE (reg. 22)

FORMS

Form 1 Application for Registration of a Drug
Form 2 Approval for Registration of a Drug
Form 3 Application for Licensing to Import, Export, Manufacture and Sell Drugs
Form 4 Approval for Licensing as per Form 3

Form HFD 1 Application for Permit to Import Habit Forming Drug
Form HFD 2 Import Permit for Habit Forming Drug
Form HFD 3 Application for permit to Export Habit Forming Drug
Form HFD 4 Export Permit for Habit Forming Drug
APPLICATION FOR REGISTRATION OF A DRUG
(All documents in English)

N.B.: Please study the notes on the reverse of each side

APPLICANT:

Name:

Postal Address:

Business Address:

Telephone/Telefax Number:

THE DRUG:

Name (Trade and INN-name) (1):

Dosage Form and Strength (2):

Colour (3):

Package Size(s):

Pharmacological Classification\(^{\text{\texttrade}}\):

Country of Origin:

Manufacturer:

The undersigned hereby declares that all information contained herein and in the appendices is correct and true.

Date: ________________________________ Signature: ________________________________

Name (block letters): ____________________________________________________________
Official and Professional Designation(5): -----------------------------------------------

(1),

(2) etc. See notes on reverse side.

NOTES

(1) International non-proprietary INN-name if available.

(2) E.g. solutions, suspension, eyedrop, emulsion, ointment, suppository, tablet, capsule or injection. In case of injections, whether a vial ampoule, dental cartridge, etc. and the contents, e.g. powder, solution, etc.

The strength to be per dosage unit. Where no dosage unit exist, other suitable unit of mass or volume of the drug.

(3) The colour shall be the final appearance of the product, e.g. white mixture in brown bottle, yellow and green capsule with white powder.

(4) Anatomical, therapeutic and chemical classification (W.H.O.) or equivalent therapeutic and pharmacological classification. Codes should be accompanied by explanation, e.g. anti-epileptic, non-steroidal anti-inflammatory, etc.

(5) The signatory shall be a registered pharmacist.
Below is a schedule of:
(a) active ingredient given in approved names, chemical names, structural and molecular formulae, specification, physical properties and quantity in dosage unit (3);
(b) inactive ingredients specifications, quantity in dosage unit and reason for inclusion;
(c) specifications of any raw material used in manufacturing whether or not present in final dosage product;
(d) chemical details of the active ingredients showing the approved name, solubility, storage requirements, etc.

### ACTIVE INGREDIENTS

<table>
<thead>
<tr>
<th>Approved name</th>
<th>Chemical name (1) and molecular formula</th>
<th>Quantity</th>
<th>Specification of Reference of such</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### INACTIVE INGREDIENTS

<table>
<thead>
<tr>
<th>Approved Name</th>
<th>Quantity</th>
<th>Specification or Reference of such</th>
<th>Purpose for Inclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
(1) Chemical names shall where possible be given in terms of the published list of an appropriate body.

(2) Specifications shall be at the level of the latest editions of the recognized references, other sources must be fully substantiated. References to the following, where applicable, shall be acceptable:

(a) British Pharmacopoeia;
(b) European Pharmacopoeia;
(c) United States Pharmacopoeia;
(d) International Pharmacopoeia; and of
(e) Any such reference that the Director may approve.
The following information about the drug shall appear on the package insert:

1. Scheduling status
2. Proprietary name (and dosage form)
3. Composition
4. Pharmacological classification (A.T.C. or equivalent)
5. Pharmacological action
6. Indications
7. Contra-indications
8. Warnings
9. Dosage and directions for use
10. Side-effects and special precautions
11. Known symptoms of overdosage and particulars of treatment
12. Conditions of registration
13. Identification
14. Presentation
15. Storage instructions
16. Registration number
17. Applicant
18. Date of publication

1, 12, 16 and 18 are for products manufactured for the Botswana market only.

(a) Scheduled status shall be determined by the Minister in accordance with section 9 of the Drugs and Related Substances Act, 1992
(b) Composition shall comprise of the active ingredients approved name and quantity per unit and the approved name and percentage of any preservative, colour and sugar included.
(c) Any recommended children's dosages and warnings shall be indicated where possible.
(d) Storage instructions shall quote temperatures (range).
(e) The number allocated in accordance with section 2 of the Act, the reference number allocated to such application by the Director followed by "Drugs Act, 1992".
(f) Date of publication shall mean the date on which the package insert was approved by the Board.
(g) Conditions of registration shall include sales category, public advertising status, etc.
CONTAINER SPECIFICATION AND CONTROL

Name of Drug:

Name of Applicant:

Dosage Form and Strength:

Below is the immediate container specification detailing type, nature, size, grade, method of closure, method of use of container, etc.

Details of immediate container analytical and other control procedures and information on contracted laboratories shall be given (1).

NOTES

1. Immediate container, in relation to a drug, means a container which is in direct contact with the drug.

PHARMACEUTICAL DOCUMENTATION

Name of Drug:

Name of Applicant:

Dosage Form and Strength:

The following information shall be included as part of the pharmaceutical documentation:

(a) Raw material specifications and analytical and control procedures;
(b) Raw material release criteria;
(c) Summarised details of final product specifications and release criteria;
(d) Description of final product analytical and other control procedures;
(e) Stability Studies (3);
(f) Manufacturing procedures (4).

NOTES

(1) All jobs carried out by specific contracted laboratories shall be mentioned - which laboratories shall be mentioned too.
(2) Specifications to include title, limits, and criteria of acceptance of all physical, chemical and microbiological parameters where applicable.

(3) Stability studies:
   i) Data indicative of at least 24 months shelf-life derived from the product in the packaging material specified in Appendix III. Where the products contain inherently unstable ingredients this requirement shall not apply.
   ii) Temperatures in Botswana can be as low as 0 degrees C and as high as 40 degreesC. Extremes of these shall be specified and tested.
   iii) The preserving ability of any antibacterial agents or preservatives in the formulation shall be specified and tested.
   iv) Data to include normal degradation products storage conditions required to maintain raw material integrity and results of qualitative results of tests carried out.
   v) Date of manufacture and batch number of samples studied for stability (minimum of two batches).

(4) Manufacturing procedures shall detail stages of manufacturing and packaging, describing type of equipment used, analytical, microbiological and in-process control procedures. Where different manufacturing facilities were used this shall be mentioned. Local manufacturers might refer to Master Manufacturing Records if possible.

N.B. Application for biological products e.g. viral vaccine, viral antiserum, bacterial vaccine, bacterial antiserum, allergan, immunoglobulin, blood products, etc., shall include a detailed description of the premises on which all procedures involved in the preparation are undertaken, including a floor plan. A mention shall be made on any other use of the said premises.
PHARMACOLOGICAL AND CLINICAL DOCUMENTATION

<table>
<thead>
<tr>
<th>Name of Drug:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name of Applicant:</td>
</tr>
<tr>
<td>Dosage Form and Strength:</td>
</tr>
</tbody>
</table>

The following shall be a summarized but detailed documentation on the pharmacological and clinical information about the drug.

NOTES

(1) Where the drug concerned is a well established drug then reference may be made to the latest edition of the standard reference textbooks.
(2) Pharmacological and clinical information shall include:
   (a) Pre-clinical toxicological information, acute toxicity, estimated average lethal dose, teratogenicity, carcinogenicity and other tests on safety.
   (b) Information on efficacy, dosage, method of administration, mode of action, side-effects and contra-indications on both laboratory animals and humans.
   (c) Details of pharmacokinetic properties, equivalence, metabolism, metabolic products and their fate.
   (d) Studies confirming the pharmaceutical or biological availability and clinical interchangeability of the drug (Where equivalence is of clinical significance).
REGISTRATION STATUS AND OTHER INFORMATION

Name of Drug:

Name of Applicant:

Dosage Form and Strength:

A. Registration status in other countries shall be submitted from three other countries where the drug is registered (1) including certificates; package insert sample from that country; countries from where the registration has been rejected, refused, deferred or cancelled and reasons for such.

B. The World Health Organisation Certificate Scheme on the Quality of Pharmaceutical Products Moving in International Commerce shall be submitted from the country of origin.

C. A list of all references to the literature shall be submitted with annotations.

D. A table of contents for all items submitted shall be forwarded.

E. Documentation should not exceed 100 pages where practicable. (Tabulation is encouraged). Where reference has been made to recognised sources, copies of these pages should not be included.

F. A sample label as would appear on the immediate container shall be attached.

G. The ex-factory price of the drug in the package sizes applied for.

(1) "Register" or "registered" in this case refer to marketing authorisation.

FOR OFFICIAL USE

<table>
<thead>
<tr>
<th>Application Number:</th>
<th>Application Fee paid (date):</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date received:</td>
<td>Cash:</td>
</tr>
<tr>
<td></td>
<td>Cheque No:</td>
</tr>
</tbody>
</table>

THE DRUG:

<table>
<thead>
<tr>
<th>Essential Drug:</th>
<th>Yes [ ]</th>
<th>No [ ]</th>
</tr>
</thead>
</table>

Therapeutic value:

<table>
<thead>
<tr>
<th>Important: [ ]</th>
<th>Less important: [ ]</th>
<th>Unimportant: [ ]</th>
</tr>
</thead>
</table>

BOARD'S DECISION:

<table>
<thead>
<tr>
<th>Refused (date):</th>
<th>Deferred (date):</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conditionally approved (date, conditions):</td>
<td></td>
</tr>
<tr>
<td>-------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Final approval (date):</td>
<td></td>
</tr>
<tr>
<td>Approved indications:</td>
<td></td>
</tr>
</tbody>
</table>

**SPECIAL CONDITIONS ETC:**

---

---
Subject to due compliance with the requirement of the Drugs and Related Substances Act, 1992, and Regulations thereto, the Director of Health Services has approved the following drug to be marketed in Botswana and entered it into the Drug Register as follows:

<table>
<thead>
<tr>
<th>Registration Number:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Name of Drug:</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Active ingredient(s), approved name or volume of the drug:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>---</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dosage Form:</th>
<th>Strength:</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Manufacturer:</th>
<th></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Manufacturing Country:</th>
<th></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Package size(s):</th>
<th></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Packaging Material:</th>
<th></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Approved Indication(s):</th>
<th></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Schedule:</th>
<th></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Special Conditions:</th>
<th></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Date granted:</th>
<th>Valid until:</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Authorization (name and stamp):</th>
<th>Signature (Dir. Health Serv.):</th>
</tr>
</thead>
</table>
REPUBLIC OF BOTSWANA
MINISTRY OF HEALTH

Application to be sent to:
Permanent Secretary
Ministry of Health
Private Bag 0038
GABORONE
Attention: Chief Pharmacist

APPLICATION FOR APPROVAL TO:

[ ] import drugs  [ ] export drugs
[ ] as wholesaler  [ ] Schedule 1, 2, 3 and 4
[ ] Schedule 4 only
[ ] as retailer  [ ] Schedule 1, 2, 3 and 4
[ ] as agent  [ ] Schedule 1, 2, 3 and 4

[ ] manufacture drugs (see also reverse page)
[ ] sell drugs
[ ] as wholesaler  [ ] Schedule 1, 2, 3 and 4
[ ] Schedule 4 only
[ ] as retailer  [ ] Schedule 1, 2, 3 and 4 (pharmacy)
[ ] Schedule 4 only

Name of applicant
(of person representing the company)

Address -------------------------------

My qualifications are (profession/education) -

-------------------------------------------------

The premises are located (address)

-------------------------------------------------

Date ________________________________ Signature of applicant
ADDITIONAL INFORMATION NEEDED FOR APPLICATION TO MANUFACTURE DRUGS

I. The following shall be the key personnel in the manufacturing plant:

<table>
<thead>
<tr>
<th>NAME</th>
<th>QUALIFICATION</th>
<th>EXPERIENCE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Supervising pharmacist</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Production pharmacist</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Quality assurance pharmacist</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The following are products intended to be manufactured (attach list showing name of product, active ingredient, strength and dosage form, include formulations and manufacturing process):
The following are the equipment to be used (attach list showing the name, type and capacity of equipment):
REPUBLIC OF BOTSWANA
MINISTRY OF HEALTH

APPROVAL FOR LICENSING

Subject to due compliance with the requirements of the Drugs and Related Substances Act, 1992 and Regulations thereto, the Director of Health Services, Ministry of Health, hereby approve for licensing:

Name of Applicant:

Address -

[ ] to import drugs  [ ] to export

[ ] J as wholesaler  [ ] Schedule 1, 2, 3 and 4
[ ] Schedule 4
[ ] as retailer  [ ] Schedule 1, 2, 3 and 4
[ ] as agent  [ ] Schedule 1, 2, 3 and 4
[ ] to manufacture drugs
[ ] to sell drugs

[ ] J as wholesaler  [ ] Schedule 1, 2, 3 and 4
[ ] Schedule 4
[ ] as retailer  [ ] Schedule 1, 2, 3 and 4
[ ] Schedule 4

at-

(premises)

Special conditions:

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

Date ___________________________ Valid until (date) ___________________________

Stamp and signature
Dir. of Health Services:
REPUBLIC OF
BOTSWANA
MINISTRY OF HEALTH

Application to be sent to:
Permanent Secretary
Ministry of Health
Private Bag 0038
GABORONE
Attention: Chief Pharmacist

APPLICATION FOR PERMIT TO IMPORT
HABIT FORMING DRUGS AND/OR PSYCHOTROPIC SUBSTANCES
(Drugs and Related Substances Act, 1992)

In accordance with the Drugs and Related Substances Act, 1992, the Single Convention on Narcotic Drugs, 1961 and the Convention on Psychotropic Substances, 1971,

I,  

(Name of Applicant)

registered as  

(Qualification and Registration Number)

or.

(Company and Address)

hereby apply for permit to import the following habit forming drugs and/or psychotropic substances:

<table>
<thead>
<tr>
<th>Item No.</th>
<th>Approved name of drug/substance and strength</th>
<th>Quantity and presentation of drug substance drug or substance</th>
<th>Purpose: medicinal, manufacture, research, scientific other (specify)</th>
<th>Stock will last (number of days if applicable)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Total number of items:
From (name and address of exporting firm)

Route of supply (by):

Port of entry (at):

Date:

Signature of applicant:

NOTES: To be accompanied by a completed order from the importing firm specifying the exporting firm.

REPUBLIC OF BOTSWANA
MINISTRY OF HEALTH

FORM HFD 2
Import Permit No

IMPORT PERMIT FOR HABIT FORMING DRUGS
AND/OR PSYCHOTROPIC SUBSTANCES

In accordance with the Drugs and Related Substances Act, 1992, the Single Convention on Narcotic Drugs, 1961 and the Convention on Psychotropic Substances, 1971, authority is here granted to:

(name, location and postal address of importing firm)

to import or acquire the Habit Forming Drugs and/or Psychotropic substances specified here under from:

(name, location and postal address of exporting firm)
<table>
<thead>
<tr>
<th>I</th>
<th>Approved name of drug/substance and presentation of preparation</th>
<th>Approved name and quantity of controlled drug/substance as base in kilograms</th>
<th>Purpose: medicinal, manufacture, research, scientific and others (specify)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Total Number of Items:

It is a condition of this permit that drugs substances imported or acquired hereunder shall not be used by the person to whom this permit is issued, otherwise than for or in accordance with the Drugs and Related Substances Act, 1992.

This authority expires on ____________________________

Drugs/substances ordered on this authority must be consigned by registered mail/road/air/sea* (Delete the inapplicable).

Route of supply (by)-------------------------------

Port of entry (at) ----------------------------------

Signature and stamp
Dir. of Health Services Date

NOTES
To be completed in quintuplicate
Original copy to be forwarded to the health authorities of exporting country to facilitate export authorization.
Duplicate to be retained by the exporter for their records.
Triplicate to be retained by the exporter and then sent with the goods to the importer along with a copy of export authorization for Customs clearance purposes.
Quadruplicate to be retained by the importer for their records.
Quintuplicate to be retained by the import authorizing office.
Application to be sent to:
Permanent Secretary
Ministry of Health
Private Bae 0038
GABORONE
Attention: Chief Pharmacist

APPLICATION FOR PERMIT TO EXPORT
HABIT FORMING DRUGS AND/OR PSYCHOTROPIC SUBSTANCES
(Drugs and Related Substances Act, 1992)

In accordance with the Drugs and Related Substances Act, 1992, the Single Convention on Narcotic Drugs, 1961 and the Convention on Psychotropic Substances, 1971,

I. __________________________________________________________
   (Name of Applicant)

registered as
   (Qualification and Registration Number)

of:
   (Company and Address)

hereby apply for permit to export the following Habit Forming drugs and/or psychotropic substances:

<table>
<thead>
<tr>
<th>Item No.</th>
<th>Approved name of drug/substance strength</th>
<th>Quantity and presentation of drug or substance</th>
<th>Purpose: medicinal research others (specify)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Total number of items:
To (name and address of importing firm):

Route of supply(by):

Port of exit (at):

Date:

Signature of applicant:

NOTES

To be accompanied by import authorization from country of destination and a completed order from the importing firm.

REPUBLIC OF BOTSWANA
MINISTRY OF HEALTH

FORM HFD 4
Export Permit No

EXPORT PERMIT FOR HABIT FORMING DRUGS
AND/OR PSYCHOTROPIC SUBSTANCES

In accordance with the Drugs and Related Substances Act, 1992, the Single Convention on Narcotic Drugs, 1961 and the Convention on Psychotropic Substances, 1971, authority is here granted to:

(name, location and postal address of exporting firm)

<table>
<thead>
<tr>
<th>Item No.</th>
<th>Approved name of drug/substance and strength</th>
<th>Quality and presentation of preparation</th>
<th>Approved name and quantity of controlled drug/substance as base in kilograms</th>
<th>Purpose: medicinal, manufacture, research, scientific and others (specify)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>-----------------------------------------------------------------------</td>
</tr>
</tbody>
</table>

-----------------
Total Number of Items:

It is a condition of this permit that drugs/substances exported hereunder shall not be used by the person to whom the permit is issued or to whom the drugs/substances are exported to otherwise than in accordance with the provisions of the Drugs and Related Substances Act, 1992 or the Single Convention on Narcotic Drugs 1961 or the Convention of Psychotropic Substances, 1971.

This authority expires on

Drugs/Substances ordered on this authority must be consigned by Registered Mail/Road/Air/Sea* (*Delete the inapplicable). The importation of these Drugs/Substance into the country of destination has been authorized by

Import Permit No  -------------------------- Dated

Route of supply (by)----------------------------------

Port of entry (at)------: --------------------------------

Signature and stamp ------------------------------------------ Date-----------------------------

Dir. of Health Services

To be completed in quintuplicate

1. Original to accompany consignment

2. Duplicate to be endorsed in accordance with the requirements of the Single Convention on Narcotic Drugs, 1961 and the Convention on Psychotropic Substances, 1971, and returned to the Chief Pharmacist, Ministry of Health P/Bag 0038, Gaborone.

3. Triplicate to be certified by the exporter and returned to the Chief Pharmacist, Ministry of Health, as soon as possible after the date of despatch.

4. Quadruplicate to be retained by the exporter for their records.

5. Quintuplicate to be retained by the export authorizing office.

MADE this 8th day of April, 1993.

B.K. TEMANE,

Minister of Health.